Hubbry Logo
VirusVirusMain
Open search
Virus
Community hub
Virus
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Contribute something
Virus
Virus
from Wikipedia

Virus
"Severe acute respiratory syndrome coronavirus 2"
SARS-CoV-2, a member of the subfamily Orthocoronavirinae
Virus classification Edit this classification
(unranked): Virus
Realms

A virus is a submicroscopic infectious agent that replicates only inside the living cells of an organism.[1] Viruses infect all life forms, from animals and plants to microorganisms, including bacteria and archaea.[2][3] Viruses are found in almost every ecosystem on Earth and are the most numerous type of biological entity.[4][5] Since Dmitri Ivanovsky's 1892 article describing a non-bacterial pathogen infecting tobacco plants and the discovery of the tobacco mosaic virus by Martinus Beijerinck in 1898,[6]: 4  more than 16,000 of the millions of virus species have been described in detail.[7][8] The study of viruses is known as virology, a subspeciality of microbiology.

When infected, a host cell is often forced to rapidly produce thousands of copies of the original virus. When not inside an infected cell or in the process of infecting a cell, viruses exist in the form of independent viral particles, or virions, consisting of (i) genetic material, i.e., long molecules of DNA or RNA that encode the structure of the proteins by which the virus acts; (ii) a protein coat, the capsid, which surrounds and protects the genetic material; and in some cases (iii) an outside envelope of lipids. The shapes of these virus particles range from simple helical and icosahedral forms to more complex structures. Most virus species have virions too small to be seen with an optical microscope and are one-hundredth the size of most bacteria.

The origins of viruses in the evolutionary history of life are still unclear. Some viruses may have evolved from plasmids, which are pieces of DNA that can move between cells. Other viruses may have evolved from bacteria. In evolution, viruses are an important means of horizontal gene transfer, which increases genetic diversity in a way analogous to sexual reproduction.[9] Viruses are considered by some biologists to be a life form, because they carry genetic material, reproduce, and evolve through natural selection, although they lack some key characteristics, such as cell structure, that are generally considered necessary criteria for defining life. Because they possess some but not all such qualities, viruses have been described as "organisms at the edge of life"[10] and as replicators.[11]

Viruses spread in many ways. One transmission pathway is through disease-bearing organisms known as vectors: for example, viruses are often transmitted from plant to plant by insects that feed on plant sap, such as aphids; and viruses in animals can be carried by blood-sucking insects. Many viruses spread in the air by coughing and sneezing, including influenza viruses, SARS-CoV-2, chickenpox, smallpox, and measles. Norovirus and rotavirus, common causes of viral gastroenteritis, are transmitted by the faecal–oral route, passed by hand-to-mouth contact or in food or water. The infectious dose of norovirus required to produce infection in humans is fewer than 100 particles.[12] HIV is one of several viruses transmitted through sexual contact and by exposure to infected blood. The variety of host cells that a virus can infect is called its host range: this is narrow for viruses specialized to infect only a few species, or broad for viruses capable of infecting many.[13]: 123–124 

Viral infections in animals provoke an immune response that usually eliminates the infecting virus. Immune responses can also be produced by vaccines, which confer an artificially acquired immunity to the specific viral infection. Some viruses, including those that cause HIV/AIDS, HPV infection, and viral hepatitis, evade these immune responses and result in chronic infections. Several classes of antiviral drugs have been developed.

Etymology

[edit]

The English word "virus" comes from the Latin word vīrus, which refers to poison and other noxious liquids. Vīrus comes from the same Indo-European root as Sanskrit viṣa, Avestan vīša, and Ancient Greek ἰός (iós), which all mean "poison". The first attested use of "virus" in English appeared in 1398 in John Trevisa's translation of Bartholomeus Anglicus's De Proprietatibus Rerum.[14][15] Virulent, from Latin virulentus ('poisonous'), dates to c. 1400.[16][17] A meaning of 'agent that causes infectious disease' is first recorded in 1728,[15] long before the discovery of viruses by Dmitri Ivanovsky in 1892. The English plural is viruses (sometimes also vira),[18] whereas the Latin word is a mass noun, which has no classically attested plural (vīra is used in Neo-Latin[19]). The adjective viral dates to 1948.[20] The term virion (plural virions), which dates from 1959,[21] is also used to refer to a single viral particle that is released from the cell and is capable of infecting other cells of the same type.[22]

Origins

[edit]

Viruses are found wherever there is life and have probably existed since living cells first evolved.[23] The origin of viruses is unclear because they do not form fossils, so molecular techniques are used to infer how they arose.[24] In addition, viral genetic material occasionally integrates into the germline of the host organisms, by which they can be passed on vertically to the offspring of the host for many generations. This provides an invaluable source of information for paleovirologists to trace back ancient viruses that existed as far back as millions of years ago.

There are three main hypotheses that aim to explain the origins of viruses:[25]

Regressive hypothesis
Viruses may have once been small cells that parasitised larger cells. Over time, genes not required by their parasitism were lost. The bacteria rickettsia and chlamydia are living cells that, like viruses, can reproduce only inside host cells. They lend support to this hypothesis, as their dependence on parasitism is likely to have caused the loss of genes that enabled them to survive outside a cell. This is also called the "degeneracy hypothesis",[6]: 16 [26]: 11  or "reduction hypothesis".[27]: 24 
Cellular origin hypothesis
Some viruses may have evolved from bits of DNA or RNA that "escaped" from the genes of a larger organism. The escaped DNA could have come from plasmids (pieces of naked DNA that can move between cells) or transposons (molecules of DNA that replicate and move around to different positions within the genes of the cell).[13]: 810  Once called "jumping genes", transposons are examples of mobile genetic elements and could be the origin of some viruses. They were discovered in maize by Barbara McClintock in 1950.[28] This is sometimes called the "vagrancy hypothesis",[6]: 16 [26]: 11–12  or the "escape hypothesis".[27]: 24 
Co-evolution hypothesis
This is also called the "virus-first hypothesis"[27]: 24  and proposes that viruses may have evolved from complex molecules of protein and nucleic acid at the same time that cells first appeared on Earth and would have been dependent on cellular life for billions of years. Viroids are molecules of RNA that are not classified as viruses because they lack a protein coat. They have characteristics that are common to several viruses and are often called subviral agents.[6]: 55  Viroids are significant pathogens of plants.[13]: 791  They do not code for proteins but interact with the host cell and use the host machinery for their replication.[29] The hepatitis delta virus of humans has an RNA genome similar to viroids but has a protein coat derived from hepatitis B virus and cannot produce one of its own. It is, therefore, a defective virus. Although hepatitis delta virus genome may replicate independently once inside a host cell, it requires the help of hepatitis B virus to provide a protein coat so that it can be transmitted to new cells.[13]: 460  In similar manner, the sputnik virophage is dependent on mimivirus, which infects the protozoan Acanthamoeba castellanii.[30] These viruses, which are dependent on the presence of other virus species in the host cell, are called "satellites" and may represent evolutionary intermediates of viroids and viruses.[26]: 777 [6]: 55–57 

In the past, there were problems with all of these hypotheses: the regressive hypothesis did not explain why even the smallest of cellular parasites do not resemble viruses in any way. The escape hypothesis did not explain the complex capsids and other structures on virus particles. The virus-first hypothesis contravened the definition of viruses in that they require host cells.[27]: 24  Viruses are now recognised as ancient and as having origins that pre-date the divergence of life into the three domains.[27]: 28  This discovery has led modern virologists to reconsider and re-evaluate these three classical hypotheses.[27]: 28 

The evidence for an ancestral world of RNA cells[27]: 26  and computer analysis of viral and host DNA sequences give a better understanding of the evolutionary relationships between different viruses and may help identify the ancestors of modern viruses. To date, such analyses have not proved which of these hypotheses is correct.[27]: 26  It seems unlikely that all currently known viruses have a common ancestor, and viruses have probably arisen numerous times in the past by one or more mechanisms.[31]

Microbiology

[edit]

Discovery

[edit]

The first evidence of the existence of viruses came from experiments with filters that had pores small enough to retain bacteria. In 1892, Dmitri Ivanovsky used one of these filters to show that sap from a diseased tobacco plant remained infectious to healthy tobacco plants despite having been filtered. Martinus Beijerinck called the filtered, infectious substance a "virus" and this discovery is considered to be the beginning of virology. The subsequent discovery and partial characterization of bacteriophages by Frederick Twort and Félix d'Herelle further catalyzed the field, and by the early 20th century many viruses had been discovered. In 1926, Thomas Milton Rivers defined viruses as obligate parasites. Viruses were demonstrated to be particles, rather than a fluid, by Wendell Meredith Stanley, and the invention of the electron microscope in 1931 allowed their complex structures to be visualised.[32]

Life properties

[edit]

Scientific opinions differ on whether viruses are a form of life or organic structures that interact with living organisms.[11] They have been described as "organisms at the edge of life",[10] since they resemble organisms in that they possess genes, evolve by natural selection,[33] and reproduce by creating multiple copies of themselves through self-assembly. Although they have genes, they do not have a cellular structure, which is often seen as the basic unit of life. Viruses do not have their own metabolism and require a host cell to make new products. They therefore cannot naturally reproduce outside a host cell[34]—although some bacteria such as rickettsia and chlamydia are considered living organisms despite the same limitation.[35][36] Accepted forms of life use cell division to reproduce, whereas viruses spontaneously assemble within cells. They differ from autonomous growth of crystals as they inherit genetic mutations while being subject to natural selection. Virus self-assembly within host cells has implications for the study of the origin of life, as it lends further credence to the hypothesis that life could have started as self-assembling organic molecules.[2] The virocell model first proposed by Patrick Forterre considers the infected cell to be the "living form" of viruses and that virus particles (virions) are analogous to spores.[37] Although the living versus non-living debate continues, the virocell model has gained some acceptance.[38]

Structure

[edit]
Virions of some of the most common human viruses with their relative size. The nucleic acids are not to scale.
Diagram of how a virus capsid can be constructed using multiple copies of just two protein molecules
Structure of tobacco mosaic virus: RNA coiled in a helix of repeating protein sub-units
Structure of icosahedral adenovirus. Electron micrograph with an illustration to show shape
Structure of chickenpox virus. They have a lipid envelope.
Structure of an icosahedral cowpea mosaic virus
Bacteriophage Escherichia virus MS2 capsid. This spherical virus also has icosahedral symmetry.

Viruses display a wide diversity of sizes and shapes, called 'morphologies'. In general, viruses are much smaller than bacteria and more than a thousand bacteriophage viruses would fit inside an Escherichia coli bacterium's cell.[39]: 98  Many viruses that have been studied are spherical and have a diameter between 20 and 300 nanometres. Some filoviruses, which are filaments, have a total length of up to 1400 nm; their diameters are only about 80 nm.[26]: 33–55  Most viruses cannot be seen with an optical microscope, so scanning and transmission electron microscopes are used to visualise them.[26]: 33–37  To increase the contrast between viruses and the background, electron-dense "stains" are used. These are solutions of salts of heavy metals, such as tungsten, that scatter the electrons from regions covered with the stain. When virions are coated with stain (positive staining), fine detail is obscured. Negative staining overcomes this problem by staining the background only.[40]

A complete virus particle, known as a virion, consists of nucleic acid surrounded by a protective coat of protein called a capsid. These are formed from protein subunits called capsomeres.[26]: 40  Viruses can have a lipid "envelope" derived from the host cell membrane. The capsid is made from proteins encoded by the viral genome and its shape serves as the basis for morphological distinction.[41][42] Virally-coded protein subunits will self-assemble to form a capsid, in general requiring the presence of the virus genome. Complex viruses code for proteins that assist in the construction of their capsid. Proteins associated with nucleic acid are known as nucleoproteins, and the association of viral capsid proteins with viral nucleic acid is called a nucleocapsid. The capsid and entire virus structure can be mechanically (physically) probed through atomic force microscopy.[43][44] In general, there are five main morphological virus types:

Helical
These viruses are composed of a single type of capsomere stacked around a central axis to form a helical structure, which may have a central cavity, or tube. This arrangement results in virions which can be short and highly rigid rods, or long and very flexible filaments. The genetic material (typically single-stranded RNA, but single-stranded DNA in some cases) is bound into the protein helix by interactions between the negatively charged nucleic acid and positive charges on the protein. Overall, the length of a helical capsid is related to the length of the nucleic acid contained within it, and the diameter is dependent on the size and arrangement of capsomeres. The well-studied tobacco mosaic virus[26]: 37 and inovirus[45] are examples of helical viruses.
Icosahedral
Most animal viruses are icosahedral or near-spherical with chiral icosahedral symmetry. A regular icosahedron is the optimum way of forming a closed shell from identical subunits. The minimum number of capsomeres required for each triangular face is 3, which gives 60 for the icosahedron. Many viruses, such as rotavirus, have more than 60 capsomers and appear spherical but they retain this symmetry. To achieve this, the capsomeres at the apices are surrounded by five other capsomeres and are called pentons. Capsomeres on the triangular faces are surrounded by six others and are called hexons.[26]: 40, 42  Hexons are in essence flat and pentons, which form the 12 vertices, are curved. The same protein may act as the subunit of both the pentamers and hexamers or they may be composed of different proteins.[46]
Prolate
This is an icosahedron elongated along the fivefold axis and is a common arrangement of the heads of bacteriophages. This structure is composed of a cylinder with a cap at either end.[47]
Enveloped
Some species of virus envelop themselves in a modified form of one of the cell membranes, either the outer membrane surrounding an infected host cell or internal membranes such as a nuclear membrane or endoplasmic reticulum, thus gaining an outer lipid bilayer known as a viral envelope. This membrane is studded with proteins coded for by the viral genome and host genome; the lipid membrane itself and any carbohydrates present originate entirely from the host. Influenza virus, HIV (which causes AIDS), and severe acute respiratory syndrome coronavirus 2 (which causes COVID-19)[48] use this strategy. Most enveloped viruses are dependent on the envelope for their infectivity.[26]: 42–43 
Complex
These viruses possess a capsid that is neither purely helical nor purely icosahedral, and that may possess extra structures such as protein tails or a complex outer wall. Some bacteriophages, such as Enterobacteria phage T4, have a complex structure consisting of an icosahedral head bound to a helical tail, which may have a hexagonal base plate with protruding protein tail fibres. This tail structure acts like a molecular syringe, attaching to the bacterial host and then injecting the viral genome into the cell.[49]

The poxviruses are large, complex viruses that have an unusual morphology. The viral genome is associated with proteins within a central disc structure known as a nucleoid. The nucleoid is surrounded by a membrane and two lateral bodies of unknown function. The virus has an outer envelope with a thick layer of protein studded over its surface. The whole virion is slightly pleomorphic, ranging from ovoid to brick-shaped.[50]

Giant viruses

[edit]

Mimivirus is one of the largest characterised viruses, with a capsid diameter of 400 nm. Protein filaments measuring 100 nm project from the surface. The capsid appears hexagonal under an electron microscope, therefore the capsid is probably icosahedral.[51] In 2011, researchers discovered the largest then known virus in samples of water collected from the ocean floor off the coast of Las Cruces, Chile. Provisionally named Megavirus chilensis, it can be seen with a basic optical microscope.[52] In 2013, the Pandoravirus genus was discovered in Chile and Australia, and has genomes about twice as large as Megavirus and Mimivirus.[53] All giant viruses have dsDNA genomes and they are classified into several families: Mimiviridae, Pithoviridae, Pandoraviridae, Phycodnaviridae, and the Mollivirus genus.[54]

Some viruses that infect Archaea have complex structures unrelated to any other form of virus, with a wide variety of unusual shapes, ranging from spindle-shaped structures to viruses that resemble hooked rods, teardrops or even bottles. Other archaeal viruses resemble the tailed bacteriophages, and can have multiple tail structures.[55]

Genome

[edit]
Genomic diversity among viruses
Property Parameters
Nucleic acid
  • DNA
  • RNA
  • Both DNA and RNA (one or the other at different stages in the life cycle)
Shape
  • Linear
  • Circular
  • Segmented
Strandedness
  • Single-stranded (ss)
  • Double-stranded (ds)
  • Double-stranded with regions of single-strandedness
Sense
  • Positive sense (+)
  • Negative sense (−)
  • Ambisense (+/−)

An enormous variety of genomic structures can be seen among viral species; as a group, they contain more structural genomic diversity than plants, animals, archaea, or bacteria. There are millions of different types of viruses,[8] although fewer than 7,000 types have been described in detail.[6]: 49  As of January 2021, the NCBI Virus genome database has more than 193,000 complete genome sequences,[56] but there are doubtlessly many more to be discovered.[57][58]

A virus has either a DNA or an RNA genome and is called a DNA virus or an RNA virus, respectively. Some RNA viruses, for example retroviruses, have a stage in their replication cycle where the genome is encoded in DNA.[59] Most viruses have RNA genomes. Plant viruses tend to have single-stranded RNA genomes and bacteriophages tend to have double-stranded DNA genomes.[26]: 96–99 

Viral genomes are circular, as in the polyomaviruses, or linear, as in the adenoviruses. The type of nucleic acid is irrelevant to the shape of the genome. Among RNA viruses and certain DNA viruses, the genome is often divided into separate parts, in which case it is called segmented. For RNA viruses, each segment often codes for only one protein and they are usually found together in one capsid. All segments are not required to be in the same virion for the virus to be infectious, as demonstrated by brome mosaic virus and several other plant viruses.[26]: 33–35 

A viral genome, irrespective of nucleic acid type, is almost always either single-stranded (ss) or double-stranded (ds). Single-stranded genomes consist of an unpaired nucleic acid, analogous to one-half of a ladder split down the middle. Double-stranded genomes consist of two complementary paired nucleic acids, analogous to a ladder. The virus particles of some virus families, such as those belonging to the Hepadnaviridae, contain a genome that is partially double-stranded and partially single-stranded.[26]: 96–99 

For most viruses with RNA genomes and some with single-stranded DNA (ssDNA) genomes, the single strands are said to be either positive-sense (called the 'plus-strand') or negative-sense (called the 'minus-strand'), depending on if they are complementary to the viral messenger RNA (mRNA). Positive-sense viral RNA is in the same sense as viral mRNA and thus at least a part of it can be immediately translated by the host cell. Negative-sense viral RNA is complementary to mRNA and thus must be converted to positive-sense RNA by an RNA-dependent RNA polymerase before translation. DNA nomenclature for viruses with genomic ssDNA is similar to RNA nomenclature, in that positive-strand viral ssDNA is identical in sequence to the viral mRNA and is thus a coding strand, while negative-sense viral ssDNA is complementary to the viral mRNA and is thus a template strand.[26]: 96–99  Several types of ssDNA and ssRNA viruses have genomes that are ambisense in that transcription can occur off both strands in a double-stranded replicative intermediate. Examples include geminiviruses, which are ssDNA plant viruses and arenaviruses, which are ssRNA viruses of animals.[60]

Genome size

[edit]

Genome size varies greatly between species. The smallest—the ssDNA circoviruses, family Circoviridae—code for only two proteins and have a genome size of only two kilobases;[61] the largest—the pandoraviruses—have genome sizes of around two megabases which code for about 2500 proteins.[53] Virus genes rarely have introns and often are arranged in the genome so that they overlap.[62]

In general, RNA viruses have smaller genome sizes than DNA viruses because of a higher error-rate when replicating, and have a maximum upper size limit.[24] Beyond this, errors when replicating render the virus useless or uncompetitive. To compensate, RNA viruses often have segmented genomes—the genome is split into smaller molecules—thus reducing the chance that an error in a single-component genome will incapacitate the entire genome. In contrast, DNA viruses generally have larger genomes because of the high fidelity of their replication enzymes.[63] Single-strand DNA viruses are an exception to this rule, as mutation rates for these genomes can approach the extreme of the ssRNA virus case.[64]

Genetic mutation and recombination

[edit]
Evolution mechanisms of Influenza A virus. (A) Antigenic Drift: Gradual accumulation of mutations in the genome of IAVs leads to emergence of new virus variants. (B) Antigenic Shift: The reassortment of genetic segments between two or more invading IAVs in a host cell can lead to emergence of an antigenically novel subtype.

Viruses undergo genetic change by several mechanisms. These include a process called antigenic drift where individual bases in the DNA or RNA mutate to other bases. Most of these point mutations are "silent"—they do not change the protein that the gene encodes—but others can confer evolutionary advantages such as resistance to antiviral drugs.[65][66] Antigenic shift occurs when there is a major change in the genome of the virus. This can be a result of recombination or reassortment. The Influenza A virus is highly prone to reassortment; occasionally this has resulted in novel strains which have caused pandemics.[67] RNA viruses often exist as quasispecies or swarms of viruses of the same species but with slightly different genome nucleoside sequences. Such quasispecies are a prime target for natural selection.[68]

Segmented genomes confer evolutionary advantages; different strains of a virus with a segmented genome can shuffle and combine genes and produce progeny viruses (or offspring) that have unique characteristics. This is called reassortment or 'viral sex'.[69]

Genetic recombination is a process by which a strand of DNA (or RNA) is broken and then joined to the end of a different DNA (or RNA) molecule. This can occur when viruses infect cells simultaneously and studies of viral evolution have shown that recombination has been rampant in the species studied.[70] Recombination is common to both RNA and DNA viruses.[71][72]

Coronaviruses have a single-strand positive-sense RNA genome. Replication of the genome is catalyzed by an RNA-dependent RNA polymerase. The mechanism of recombination used by coronaviruses likely involves template switching by the polymerase during genome replication.[73] This process appears to be an adaptation for coping with genome damage.[74]

Replication cycle

[edit]
A typical virus replication cycle
Some bacteriophages inject their genomes into bacterial cells (not to scale)

Viral populations do not grow through cell division, because they are acellular. Instead, they use the machinery and metabolism of a host cell to produce multiple copies of themselves, and they assemble in the cell.[75] When infected, the host cell is forced to rapidly produce thousands of copies of the original virus.[76]

Their life cycle differs greatly between species, but there are six basic stages in their life cycle:[26]: 75–91 

Attachment is a specific binding between viral capsid proteins and specific receptors on the host cellular surface. This specificity determines the host range and type of host cell of a virus. For example, HIV infects a limited range of human leucocytes. This is because its surface protein, gp120, specifically interacts with the CD4 molecule—a chemokine receptor—which is most commonly found on the surface of CD4+ T-Cells. This mechanism has evolved to favour those viruses that infect only cells in which they are capable of replication. Attachment to the receptor can induce the viral envelope protein to undergo changes that result in the fusion of viral and cellular membranes, or changes of non-enveloped virus surface proteins that allow the virus to enter.[77]

Penetration or viral entry follows attachment: Virions enter the host cell through receptor-mediated endocytosis or membrane fusion. The infection of plant and fungal cells is different from that of animal cells. Plants have a rigid cell wall made of cellulose, and fungi one of chitin, so most viruses can get inside these cells only after trauma to the cell wall.[6]: 70  Nearly all plant viruses (such as tobacco mosaic virus) can also move directly from cell to cell, in the form of single-stranded nucleoprotein complexes, through pores called plasmodesmata.[78] Bacteria, like plants, have strong cell walls that a virus must breach to infect the cell. Given that bacterial cell walls are much thinner than plant cell walls due to their much smaller size, some viruses have evolved mechanisms that inject their genome into the bacterial cell across the cell wall, while the viral capsid remains outside.[6]: 71 

Uncoating is a process in which the viral capsid is removed: This may be by degradation by viral enzymes or host enzymes or by simple dissociation; the end-result is the releasing of the viral genomic nucleic acid.[79]

Replication of viruses involves primarily multiplication of the genome. Replication involves the synthesis of viral messenger RNA (mRNA) from "early" genes (with exceptions for positive-sense RNA viruses), viral protein synthesis, possible assembly of viral proteins, then viral genome replication mediated by early or regulatory protein expression. This may be followed, for complex viruses with larger genomes, by one or more further rounds of mRNA synthesis: "late" gene expression is, in general, of structural or virion proteins.[80]

Assembly – Following the structure-mediated self-assembly of the virus particles, some modification of the proteins often occurs. In viruses such as HIV, this modification (sometimes called maturation) occurs after the virus has been released from the host cell.[81]

Release – Viruses can be released from the host cell by lysis, a process that kills the cell by bursting its membrane and cell wall if present: this is a feature of many bacterial and some animal viruses. Some viruses undergo a lysogenic cycle where the viral genome is incorporated by genetic recombination into a specific place in the host's chromosome. The viral genome is then known as a "provirus" or, in the case of bacteriophages a "prophage".[13]: 836  Whenever the host divides, the viral genome is also replicated. The viral genome is mostly silent within the host. At some point, the provirus or prophage may give rise to the active virus, which may lyse the host cells.[6]: 243–259  Enveloped viruses (e.g., HIV) typically are released from the host cell by budding. During this process, the virus acquires its envelope, which is a modified piece of the host's plasma or other, internal membrane.[6]: 185–187 

Genome replication

[edit]

The genetic material within virus particles, and the method by which the material is replicated, varies considerably between different types of viruses.

DNA viruses
The genome replication of most DNA viruses takes place in the cell's nucleus. If the cell has the appropriate receptor on its surface, these viruses enter the cell either by direct fusion with the cell membrane (e.g., herpesviruses) or—more usually—by receptor-mediated endocytosis. Most DNA viruses are entirely dependent on the host cell's DNA and RNA synthesising machinery and RNA processing machinery. Viruses with larger genomes may encode much of this machinery themselves. In eukaryotes, the viral genome must cross the cell's nuclear membrane to access this machinery, while in bacteria it need only enter the cell.[13]: 118 [26]: 78 
RNA viruses
Replication of RNA viruses usually takes place in the cytoplasm. RNA viruses can be placed into four different groups depending on their modes of replication. The polarity (whether or not it can be used directly by ribosomes to make proteins) of single-stranded RNA viruses largely determines the replicative mechanism; the other major criterion is whether the genetic material is single-stranded or double-stranded. All RNA viruses use their own RNA replicase enzymes to create copies of their genomes.[26]: 79 
Reverse transcribing viruses
Reverse transcribing viruses have ssRNA (Retroviridae, Metaviridae, Pseudoviridae) or dsDNA (Caulimoviridae, and Hepadnaviridae) in their particles. Reverse transcribing viruses with RNA genomes (retroviruses) use a DNA intermediate to replicate, whereas those with DNA genomes (pararetroviruses) use an RNA intermediate during genome replication. Both types use a reverse transcriptase, or RNA-dependent DNA polymerase enzyme, to carry out the nucleic acid conversion. Retroviruses integrate the DNA produced by reverse transcription into the host genome as a provirus as a part of the replication process; pararetroviruses do not, although integrated genome copies of especially plant pararetroviruses can give rise to infectious virus.[82] They are susceptible to antiviral drugs that inhibit the reverse transcriptase enzyme, e.g. zidovudine and lamivudine. An example of the first type is HIV, which is a retrovirus. Examples of the second type are the Hepadnaviridae, which includes Hepatitis B virus.[26]: 88–89 

Cytopathic effects on the host cell

[edit]

The range of structural and biochemical effects that viruses have on the host cell is extensive.[26]: 115–146  These are called 'cytopathic effects'.[26]: 115  Most virus infections eventually result in the death of the host cell. The causes of death include cell lysis, alterations to the cell's surface membrane and apoptosis.[83] Often cell death is caused by cessation of its normal activities because of suppression by virus-specific proteins, not all of which are components of the virus particle.[84] The distinction between cytopathic and harmless is gradual. Some viruses, such as Epstein–Barr virus, can cause cells to proliferate without causing malignancy,[85] while others, such as papillomaviruses, are established causes of cancer.[86]

Dormant and latent infections

[edit]

Some viruses cause no apparent changes to the infected cell. Cells in which the virus is latent and inactive show few signs of infection and often function normally.[87] This causes persistent infections and the virus is often dormant for many months or years. This is often the case with herpes viruses.[88][89]

Host range

[edit]

Viruses are by far the most abundant biological entities on Earth and they outnumber all the others put together.[90] They infect all types of cellular life including animals, plants, bacteria and fungi.[6]: 49  Different types of viruses can infect only a limited range of hosts and many are species-specific. Some, such as smallpox virus for example, can infect only one species—in this case humans,[13]: 643  and are said to have a narrow host range. Other viruses, such as rabies virus, can infect different species of mammals and are said to have a broad range.[13]: 631  The viruses that infect plants are harmless to animals, and most viruses that infect other animals are harmless to humans.[6]: 272  The host range of some bacteriophages is limited to a single strain of bacteria and they can be used to trace the source of outbreaks of infections by a method called phage typing.[91] The complete set of viruses in an organism or habitat is called the virome; for example, all human viruses constitute the human virome.[92]

Novel viruses

[edit]

A novel virus is one that has not previously been recorded. It can be a virus that is isolated from its natural reservoir or isolated as the result of spread to an animal or human host where the virus had not been identified before. It can be an emergent virus, one that represents a new virus, but it can also be an extant virus that has not been previously identified.[93] The SARS-CoV-2 coronavirus that caused the COVID-19 pandemic is an example of a novel virus.[94]

Classification

[edit]

Classification seeks to describe the diversity of viruses by naming and grouping them on the basis of similarities. In 1962, André Lwoff, Robert Horne, and Paul Tournier were the first to develop a means of virus classification, based on the Linnaean hierarchical system.[95] This system based classification on phylum, class, order, family, genus, and species. Viruses were grouped according to their shared properties (not those of their hosts) and the type of nucleic acid forming their genomes.[96] In 1966, the International Committee on Taxonomy of Viruses (ICTV) was formed. The system proposed by Lwoff, Horne and Tournier was initially not accepted by the ICTV because the small genome size of viruses and their high rate of mutation made it difficult to determine their ancestry beyond order. As such, the Baltimore classification system has come to be used to supplement the more traditional hierarchy.[97] Starting in 2018, the ICTV began to acknowledge deeper evolutionary relationships between viruses that have been discovered over time and adopted a 15-rank classification system ranging from realm to species.[98] Additionally, some species within the same genus are grouped into a genogroup.[99][100]

ICTV classification

[edit]

The ICTV developed the current classification system and wrote guidelines that put a greater weight on certain virus properties to maintain family uniformity. A unified taxonomy (a universal system for classifying viruses) has been established.[101] Only a small part of the total diversity of viruses has been studied.[102] As of 2024, 7 realms, 11 kingdoms, 22 phyla, 4 subphyla, 49 classes, 93 orders, 12 suborders, 368 families, 213 subfamilies, 3,769 genera, 86 subgenera, and 16,215 species of viruses have been defined by the ICTV.[7]

The general taxonomic structure of taxon ranges and the suffixes used in taxonomic names are shown hereafter. As of 2022, the ranks of subrealm, subkingdom, and subclass are unused, whereas all other ranks are in use.[7]

Realm (-viria)
Subrealm (-vira)
Kingdom (-virae)
Subkingdom (-virites)
Phylum (-viricota)
Subphylum (-viricotina)
Class (-viricetes)
Subclass (-viricetidae)
Order (-virales)
Suborder (-virineae)
Family (-viridae)
Subfamily (-virinae)
Genus (-virus)
Subgenus (-virus)
Species

Baltimore classification

[edit]
A diagram showing how the Baltimore Classification is based on a virus's DNA or RNA and method of mRNA synthesis
The Baltimore Classification of viruses is based on the method of viral mRNA synthesis

The Nobel Prize-winning biologist David Baltimore devised the Baltimore classification system.[103][104] The ICTV classification system is used in conjunction with the Baltimore classification system in modern virus classification.[105][106][107]

The Baltimore classification of viruses is based on the mechanism of mRNA production. Viruses must generate mRNAs from their genomes to produce proteins and replicate themselves, but different mechanisms are used to achieve this in each virus family. Viral genomes may be single-stranded (ss) or double-stranded (ds), RNA or DNA, and may or may not use reverse transcriptase (RT). In addition, ssRNA viruses may be either sense (+) or antisense (−). This classification places viruses into seven groups:


Role in human disease

[edit]
A photograph of the upper body of a man labelled with the names of viruses that infect the different parts
Overview of the main types of viral infection and the most notable species involved[108]

Examples of common human diseases caused by viruses include the common cold, influenza, chickenpox, and cold sores. Many serious diseases such as rabies, Ebola virus disease, AIDS (HIV), avian influenza, and SARS are caused by viruses. The relative ability of viruses to cause disease is described in terms of virulence. Other diseases are under investigation to discover if they have a virus as the causative agent, such as the possible connection between human herpesvirus 6 (HHV6) and neurological diseases such as multiple sclerosis and chronic fatigue syndrome.[109] There is controversy over whether the bornavirus, previously thought to cause neurological diseases in horses, could be responsible for psychiatric illnesses in humans.[110]

Viruses have different mechanisms by which they produce disease in an organism, which depends largely on the viral species. Mechanisms at the cellular level primarily include cell lysis, the breaking open and subsequent death of the cell. In multicellular organisms, if enough cells die, the whole organism will start to suffer the effects. Although viruses cause disruption of healthy homeostasis, resulting in disease, they may exist relatively harmlessly within an organism. An example would include the ability of the herpes simplex virus, which causes cold sores, to remain in a dormant state within the human body. This is called latency[111] and is a characteristic of the herpes viruses, including Epstein–Barr virus, which causes glandular fever, and varicella zoster virus, which causes chickenpox and shingles. Most people have been infected with at least one of these types of herpes virus.[112] These latent viruses might sometimes be beneficial, as the presence of the virus can increase immunity against bacterial pathogens, such as Yersinia pestis.[113]

Some viruses can cause lifelong or chronic infections, where the viruses continue to replicate in the body despite the host's defence mechanisms.[114] This is common in hepatitis B virus and hepatitis C virus infections. People chronically infected are known as carriers, as they serve as reservoirs of infectious virus.[115] In populations with a high proportion of carriers, the disease is said to be endemic.[116]

Epidemiology

[edit]

Viral epidemiology is the branch of medical science that deals with the transmission and control of virus infections in humans. Transmission of viruses can be vertical, which means from mother to child, or horizontal, which means from person to person. Examples of vertical transmission include hepatitis B virus and HIV, where the baby is born already infected with the virus.[117] Another, more rare, example is the varicella zoster virus, which, although causing relatively mild infections in children and adults, can be fatal to the foetus and newborn baby.[118]

Horizontal transmission is the most common mechanism of spread of viruses in populations.[119] Horizontal transmission can occur when body fluids are exchanged during sexual activity, by exchange of saliva or when contaminated food or water is ingested. It can also occur when aerosols containing viruses are inhaled or by insect vectors such as when infected mosquitoes penetrate the skin of a host.[119] Most types of viruses are restricted to just one or two of these mechanisms and they are referred to as "respiratory viruses" or "enteric viruses" and so forth. The rate or speed of transmission of viral infections depends on factors that include population density, the number of susceptible individuals, (i.e., those not immune),[120] the quality of healthcare and the weather.[121]

Epidemiology is used to break the chain of infection in populations during outbreaks of viral diseases.[13]: 264  Control measures are used that are based on knowledge of how the virus is transmitted. It is important to find the source, or sources, of the outbreak and to identify the virus. Once the virus has been identified, the chain of transmission can sometimes be broken by vaccines. When vaccines are not available, sanitation and disinfection can be effective. Often, infected people are isolated from the rest of the community, and those that have been exposed to the virus are placed in quarantine.[13]: 894  To control the outbreak of foot-and-mouth disease in cattle in Britain in 2001, thousands of cattle were slaughtered.[122] Most viral infections of humans and other animals have incubation periods during which the infection causes no signs or symptoms.[13]: 170  Incubation periods for viral diseases range from a few days to weeks, but are known for most infections.[13]: 170–172  Somewhat overlapping, but mainly following the incubation period, there is a period of communicability—a time when an infected individual or animal is contagious and can infect another person or animal.[13]: 170–172  This, too, is known for many viral infections, and knowledge of the length of both periods is important in the control of outbreaks.[13]: 272  When outbreaks cause an unusually high proportion of cases in a population, community, or region, they are called epidemics. If outbreaks spread worldwide, they are called pandemics.[13]: 891 

Epidemics and pandemics

[edit]
An electron micrograph of the virus that caused Spanish influenza
Transmission electron microscope image of a recreated 1918 influenza virus

A pandemic is a worldwide epidemic. The 1918 flu pandemic, which lasted until 1919, was a category 5 influenza pandemic caused by an unusually severe and deadly influenza A virus. The victims were often healthy young adults, in contrast to most influenza outbreaks, which predominantly affect juvenile, elderly, or otherwise-weakened patients.[26]: 409–415  Older estimates say it killed 40–50 million people,[123] while more recent research suggests that it may have killed as many as 100 million people, or 5% of the world's population in 1918.[124]

Although viral pandemics are rare events, HIV—which evolved from viruses found in monkeys and chimpanzees—has been pandemic since at least the 1980s.[125] During the 20th century there were four pandemics caused by influenza virus and those that occurred in 1918, 1957 and 1968 were severe.[126] Most researchers believe that HIV originated in sub-Saharan Africa during the 20th century;[127] it is now a pandemic, with an estimated 37.9 million people now living with the disease worldwide.[128] There were about 770,000 deaths from AIDS in 2018.[129] The Joint United Nations Programme on HIV/AIDS (UNAIDS) and the World Health Organization (WHO) estimate that AIDS has killed more than 25 million people since it was first recognised on 5 June 1981, making it one of the most destructive epidemics in recorded history.[130] In 2007 there were 2.7 million new HIV infections and 2 million HIV-related deaths.[131]

Ebola (top) and Marburg viruses (bottom)

Several highly lethal viral pathogens are members of the Filoviridae. Filoviruses are filament-like viruses that cause viral hemorrhagic fever, and include ebolaviruses and marburgviruses. Marburg virus, first discovered in 1967, attracted widespread press attention in April 2005 for an outbreak in Angola.[132] Ebola virus disease has also caused intermittent outbreaks with high mortality rates since 1976 when it was first identified. The worst and most recent one is the 2013–2016 West Africa epidemic.[133]

Except for smallpox, most pandemics are caused by newly evolved viruses. These "emergent" viruses are usually mutants of less harmful viruses that have circulated previously either in humans or other animals.[134]

Severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) are caused by new types of coronaviruses. Other coronaviruses are known to cause mild infections in humans,[135] so the virulence and rapid spread of SARS infections—that by July 2003 had caused around 8,000 cases and 800 deaths—was unexpected and most countries were not prepared.[136]

A related coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), thought to have originated in bats, emerged in Wuhan, China in November 2019 and spread rapidly around the world. Infections with the virus caused the COVID-19 pandemic that started in 2020.[94][137][138] Unprecedented restrictions in peacetime were placed on international travel,[139] and curfews were imposed in several major cities worldwide in response to the pandemic.[140]

Cancer

[edit]

Viruses are an established cause of cancer in humans and other species. Viral cancers occur only in a minority of infected persons (or animals). Cancer viruses come from a range of virus families, including both RNA and DNA viruses, and so there is no single type of "oncovirus" (an obsolete term originally used for acutely transforming retroviruses). The development of cancer is determined by a variety of factors such as host immunity[141] and mutations in the host.[142] Viruses accepted to cause human cancers include some genotypes of human papillomavirus, hepatitis B virus, hepatitis C virus, Epstein–Barr virus, Kaposi's sarcoma-associated herpesvirus and human T-lymphotropic virus. The most recently discovered human cancer virus is a polyomavirus (Merkel cell polyomavirus) that causes most cases of a rare form of skin cancer called Merkel cell carcinoma.[143] Hepatitis viruses can develop into a chronic viral infection that leads to liver cancer.[144][145] Infection by human T-lymphotropic virus can lead to tropical spastic paraparesis and adult T-cell leukaemia.[146] Human papillomaviruses are an established cause of cancers of cervix, skin, anus, and penis.[147] Within the Herpesviridae, Kaposi's sarcoma-associated herpesvirus causes Kaposi's sarcoma and body-cavity lymphoma, and Epstein–Barr virus causes Burkitt's lymphoma, Hodgkin's lymphoma, B lymphoproliferative disorder, and nasopharyngeal carcinoma.[148] Merkel cell polyomavirus closely related to SV40 and mouse polyomaviruses that have been used as animal models for cancer viruses for over 50 years.[149]

Host defence mechanisms

[edit]

The body's first line of defence against viruses is the innate immune system. This comprises cells and other mechanisms that defend the host from infection in a non-specific manner. This means that the cells of the innate system recognise, and respond to, pathogens in a generic way, but, unlike the adaptive immune system, it does not confer long-lasting or protective immunity to the host.[150]

RNA interference is an important innate defence against viruses.[151] Many viruses have a replication strategy that involves double-stranded RNA (dsRNA). When such a virus infects a cell, it releases its RNA molecule or molecules, which immediately bind to a protein complex called a dicer that cuts the RNA into smaller pieces. A biochemical pathway—the RISC complex—is activated, which ensures cell survival by degrading the viral mRNA. Rotaviruses have evolved to avoid this defence mechanism by not uncoating fully inside the cell, and releasing newly produced mRNA through pores in the particle's inner capsid. Their genomic dsRNA remains protected inside the core of the virion.[152][153]

When the adaptive immune system of a vertebrate encounters a virus, it produces specific antibodies that bind to the virus and often render it non-infectious. This is called humoral immunity. Two types of antibodies are important. The first, called IgM, is highly effective at neutralising viruses but is produced by the cells of the immune system only for a few weeks. The second, called IgG, is produced indefinitely. The presence of IgM in the blood of the host is used to test for acute infection, whereas IgG indicates an infection sometime in the past.[154] IgG antibody is measured when tests for immunity are carried out.[155]

Antibodies can continue to be an effective defence mechanism even after viruses have managed to gain entry to the host cell. A protein that is in cells, called TRIM21, can attach to the antibodies on the surface of the virus particle. This primes the subsequent destruction of the virus by the enzymes of the cell's proteosome system.[156]

Two spherical rotavirus particles, one is coated with antibody which looks like many small birds, regularly spaced on the surface of the virus
Two rotaviruses: the one on the right is coated with antibodies that prevent its attachment to cells and infecting them.

A second defence of vertebrates against viruses is called cell-mediated immunity and involves immune cells known as T cells. The body's cells constantly display short fragments of their proteins on the cell's surface, and, if a T cell recognises a suspicious viral fragment there, the host cell is destroyed by 'killer T' cells and the virus-specific T-cells proliferate. Cells such as the macrophage are specialists at this antigen presentation.[157] The production of interferon is an important host defence mechanism. This is a hormone produced by the body when viruses are present. Its role in immunity is complex; it eventually stops the viruses from reproducing by killing the infected cell and its close neighbours.[158]

Not all virus infections produce a protective immune response in this way. HIV evades the immune system by constantly changing the amino acid sequence of the proteins on the surface of the virion. This is known as "escape mutation" as the viral epitopes escape recognition by the host immune response. These persistent viruses evade immune control by sequestration, blockade of antigen presentation, cytokine resistance, evasion of natural killer cell activities, escape from apoptosis, and antigenic shift.[159] Other viruses, called 'neurotropic viruses', are disseminated by neural spread where the immune system may be unable to reach them due to immune privilege.[160]

Prevention and treatment

[edit]

Because viruses use vital metabolic pathways within host cells to replicate, they are difficult to eliminate without using drugs that cause toxic effects to host cells in general. The most effective medical approaches to viral diseases are vaccinations to provide immunity to infection, and antiviral drugs that selectively interfere with viral replication.

Vaccines

[edit]

Vaccination is a cheap and effective way of preventing infections by viruses. Vaccines were used to prevent viral infections long before the discovery of the actual viruses. Their use has resulted in a dramatic decline in morbidity (illness) and mortality (death) associated with viral infections such as polio, measles, mumps and rubella.[161] Smallpox infections have been eradicated.[162] Vaccines are available to prevent over thirteen viral infections of humans,[163] and more are used to prevent viral infections of animals.[164] Vaccines can consist of live-attenuated or killed viruses, viral proteins (antigens), or RNA.[165][166] Live vaccines contain weakened forms of the virus, which do not cause the disease but, nonetheless, confer immunity. Such viruses are called attenuated. Live vaccines can be dangerous when given to people with a weak immunity (who are described as immunocompromised), because in these people, the weakened virus can cause the original disease.[167] Biotechnology and genetic engineering techniques are used to produce subunit vaccines. These vaccines use only the capsid proteins of the virus. Hepatitis B vaccine is an example of this type of vaccine.[168] Subunit vaccines are safe for immunocompromised patients because they cannot cause the disease.[169] The yellow fever virus vaccine, a live-attenuated strain called 17D, is probably the safest and most effective vaccine ever generated.[170]

Antiviral drugs

[edit]
The structure of the DNA base guanosine and the antiviral drug acyclovir

Antiviral drugs are often nucleoside analogues (fake DNA building-blocks), which viruses mistakenly incorporate into their genomes during replication.[171] The life-cycle of the virus is then halted because the newly synthesised DNA is inactive. This is because these analogues lack the hydroxyl groups, which, along with phosphorus atoms, link together to form the strong "backbone" of the DNA molecule. This is called DNA chain termination.[172] Examples of nucleoside analogues are aciclovir for Herpes simplex virus infections and lamivudine for HIV and hepatitis B virus infections. Aciclovir is one of the oldest and most frequently prescribed antiviral drugs.[173] Other antiviral drugs in use target different stages of the viral life cycle. HIV is dependent on a proteolytic enzyme called the HIV-1 protease for it to become fully infectious. There is a large class of drugs called protease inhibitors that inactivate this enzyme.[174] There are around thirteen classes of antiviral drugs each targeting different viruses or stages of viral replication.[171]

Hepatitis C is caused by an RNA virus. In 80% of people infected, the disease is chronic, and without treatment, they are infected for the remainder of their lives. There are effective treatments that use direct-acting antivirals.[175] The treatment of chronic carriers of the hepatitis B virus has also been developed by using similar strategies that include lamivudine and other anti-viral drugs.[176]

Infection in other species

[edit]

Viruses infect all cellular life and, although viruses occur universally, each cellular species has its own specific range that often infects only that species.[6]: 3  Some viruses, called satellites, can replicate only within cells that have already been infected by another virus.[30]

Animal viruses

[edit]

Viruses are important pathogens of livestock. Diseases such as foot-and-mouth disease and bluetongue are caused by viruses.[177] Companion animals such as cats, dogs, and horses, if not vaccinated, are susceptible to serious viral infections. Canine parvovirus is caused by a small DNA virus and infections are often fatal in pups.[178] Like all invertebrates, the honey bee is susceptible to many viral infections.[179] Most viruses co-exist harmlessly in their host and cause no signs or symptoms of disease.[6]: 4 

Plant viruses

[edit]
Peppers infected by mild mottle virus

There are many types of plant viruses, but often they cause only a loss of yield, and it is not economically viable to try to control them. Plant viruses are often spread from plant to plant by organisms, known as vectors. These are usually insects, but some fungi, nematode worms, single-celled organisms, and parasitic plants are vectors.[180] When control of plant virus infections is considered economical, for perennial fruits, for example, efforts are concentrated on killing the vectors and removing alternate hosts such as weeds.[13]: 802  Plant viruses cannot infect humans and other animals because they can reproduce only in living plant cells.[13]: 799–807 

Originally from Peru, the potato has become a staple crop worldwide.[181] The potato virus Y causes disease in potatoes and related species including tomatoes and peppers. In the 1980s, this virus acquired economical importance when it proved difficult to control in seed potato crops. Transmitted by aphids, this virus can reduce crop yields by up to 80 per cent, causing significant losses to potato yields.[182]

Plants have elaborate and effective defence mechanisms against viruses. One of the most effective is the presence of so-called resistance (R) genes. Each R gene confers resistance to a particular virus by triggering localised areas of cell death around the infected cell, which can often be seen with the unaided eye as large spots. This stops the infection from spreading.[183] RNA interference is also an effective defence in plants.[13]: 809  When they are infected, plants often produce natural disinfectants that kill viruses, such as salicylic acid, nitric oxide, and reactive oxygen molecules.[184]

Plant virus particles or virus-like particles (VLPs) have applications in both biotechnology and nanotechnology. The capsids of most plant viruses are simple and robust structures and can be produced in large quantities either by the infection of plants or by expression in a variety of heterologous systems. Plant virus particles can be modified genetically and chemically to encapsulate foreign material and can be incorporated into supramolecular structures for use in biotechnology.[185]

Bacterial viruses

[edit]
An electron micrograph showing a portion of a bacterium covered with viruses
Transmission electron micrograph of multiple bacteriophages attached to a bacterial cell wall

Bacteriophages are a common and diverse group of viruses and are the most abundant biological entity in aquatic environments—there are up to ten times more of these viruses in the oceans than there are bacteria,[186] reaching levels of 250,000,000 bacteriophages per millilitre of seawater.[187] These viruses infect specific bacteria by binding to surface receptor molecules and then entering the cell. Within a short amount of time, in some cases, just minutes, bacterial polymerase starts translating viral mRNA into protein. These proteins go on to become either new virions within the cell, helper proteins, which help assembly of new virions, or proteins involved in cell lysis. Viral enzymes aid in the breakdown of the cell membrane, and, in the case of the T4 phage, in just over twenty minutes after injection over three hundred phages could be released.[13]: 834–835 

The major way bacteria defend themselves from bacteriophages is by producing enzymes that destroy foreign DNA. These enzymes, called restriction endonucleases, cut up the viral DNA that bacteriophages inject into bacterial cells.[188] Bacteria also contain a system that uses CRISPR sequences to retain fragments of the genomes of viruses that the bacteria have come into contact with previously, which allows them to block the virus's replication through a form of RNA interference.[189][190] This genetic system provides bacteria with acquired immunity to infection.[191]

Some bacteriophages are called "temperate" because they cause latent infections and do not immediately destroy their host cells. Instead, their DNA is incorporated with the host cell's as a prophage. These latent infections become productive when the prophage DNA is activated by stimuli such as changes in the environment.[192] The intestines of animals, including humans, contain temperate bacteriophages, which are activated by various stimuli including changes in diet and antibiotics.[193] Although first observed in bacteriophages, many other viruses are known to form proviruses including HIV.[192][194]

Archaeal viruses

[edit]

Some viruses replicate within archaea: these are DNA viruses with unusual and sometimes unique shapes.[4][55] These viruses have been studied in most detail in the thermophilic archaea, particularly the orders Sulfolobales and Thermoproteales.[195] Defences against these viruses involve RNA interference from repetitive DNA sequences within archaean genomes that are related to the genes of the viruses.[196][197] Most archaea have CRISPR–Cas systems as an adaptive defence against viruses. These enable archaea to retain sections of viral DNA, which are then used to target and eliminate subsequent infections by the virus using a process similar to RNA interference.[198]

Role in aquatic ecosystems

[edit]

Viruses are the most abundant biological entity in aquatic environments.[2] There are about ten million of them in a teaspoon of seawater.[199] Most of these viruses are bacteriophages infecting heterotrophic bacteria and cyanophages infecting cyanobacteria and they are essential to the regulation of saltwater and freshwater ecosystems.[200] Bacteriophages are harmless to plants and animals, and are essential to the regulation of marine and freshwater ecosystems[201] are important mortality agents of phytoplankton, the base of the foodchain in aquatic environments.[202] They infect and destroy bacteria in aquatic microbial communities, and are one of the most important mechanisms of recycling carbon and nutrient cycling in marine environments. The organic molecules released from the dead bacterial cells stimulate fresh bacterial and algal growth, in a process known as the viral shunt.[203] In particular, lysis of bacteria by viruses has been shown to enhance nitrogen cycling and stimulate phytoplankton growth.[204] Viral activity may also affect the biological pump, the process whereby carbon is sequestered in the deep ocean.[205]

Microorganisms constitute more than 90% of the biomass in the sea. It is estimated that viruses kill approximately 20% of this biomass each day and that there are 10 to 15 times as many viruses in the oceans as there are bacteria and archaea.[206] Viruses are also major agents responsible for the destruction of phytoplankton including harmful algal blooms,[207] The number of viruses in the oceans decreases further offshore and deeper into the water, where there are fewer host organisms.[205]

In January 2018, scientists reported that 800 million viruses, mainly of marine origin, are deposited daily from the Earth's atmosphere onto every square meter of the planet's surface, as the result of a global atmospheric stream of viruses, circulating above the weather system but below the altitude of usual airline travel, distributing viruses around the planet.[208][209]

Like any organism, marine mammals are susceptible to viral infections. In 1988 and 2002, thousands of harbour seals were killed in Europe by phocine distemper virus.[210] Many other viruses, including caliciviruses, herpesviruses, adenoviruses and parvoviruses, circulate in marine mammal populations.[205]

In December 2022, scientists reported the first observation of virovory via an experiment on pond water containing chlorovirus, which commonly infects green algae in freshwater environments. When all other microbial food sources were removed from the water, the ciliate Halteria was observed to have increased in number due to the active consumption of chlorovirus as a food source instead of its typical bacterivore diet.[211][212]

Role in evolution

[edit]

Viruses are an important natural means of transferring genes between different species, which increases genetic diversity and drives evolution.[9][213][214] It is thought that viruses played a central role in early evolution, before the diversification of the last universal common ancestor into bacteria, archaea and eukaryotes.[215] Viruses are still one of the largest reservoirs of unexplored genetic diversity on Earth.[205]

Applications

[edit]

Life sciences and medicine

[edit]
Scientist studying the H5N1 influenza virus

Viruses are important to the study of molecular and cell biology as they provide simple systems that can be used to manipulate and investigate the functions of cells.[26]: 8  The study and use of viruses have provided valuable information about aspects of cell biology.[216] For example, viruses have been useful in the study of genetics and helped our understanding of the basic mechanisms of molecular genetics, such as DNA replication, transcription, RNA processing, translation, protein transport, and immunology.

Geneticists often use viruses as vectors to introduce genes into cells that they are studying. This is useful for making the cell produce a foreign substance, or to study the effect of introducing a new gene into the genome. Similarly, virotherapy uses viruses as vectors to treat various diseases, as they can specifically target cells and DNA. It shows promising use in the treatment of cancer and in gene therapy. Eastern European scientists have used phage therapy as an alternative to antibiotics for some time, and interest in this approach is increasing, because of the high level of antibiotic resistance now found in some pathogenic bacteria.[217] The expression of heterologous proteins by viruses is the basis of several manufacturing processes that are currently being used for the production of various proteins such as vaccine antigens and antibodies. Industrial processes have been recently developed using viral vectors and several pharmaceutical proteins are currently in pre-clinical and clinical trials.[218]

Virotherapy

[edit]

Virotherapy involves the use of genetically modified viruses to treat diseases.[219] Viruses have been modified by scientists to reproduce in cancer cells and destroy them but not infect healthy cells. Talimogene laherparepvec (T-VEC), for example, is a modified herpes simplex virus that has had a gene, which is required for viruses to replicate in healthy cells, deleted and replaced with a human gene (GM-CSF) that stimulates immunity. When this virus infects cancer cells, it destroys them and in doing so the presence the GM-CSF gene attracts dendritic cells from the surrounding tissues of the body. The dendritic cells process the dead cancer cells and present components of them to other cells of the immune system.[220] Having completed successful clinical trials, the virus gained approval for the treatment of melanoma in late 2015.[221] Viruses that have been reprogrammed to kill cancer cells are called oncolytic viruses.[222]

Materials science and nanotechnology

[edit]

From the viewpoint of a materials scientist, viruses can be regarded as organic nanoparticles.[223] Their surface carries specific tools that enable them to cross the barriers of their host cells. The size and shape of viruses and the number and nature of the functional groups on their surface are precisely defined. As such, viruses are commonly used in materials science as scaffolds for covalently linked surface modifications. A particular quality of viruses is that they can be tailored by directed evolution. The powerful techniques developed by life sciences are becoming the basis of engineering approaches towards nanomaterials, opening a wide range of applications far beyond biology and medicine.[224] Because of their size, shape, and well-defined chemical structures, viruses have been used as templates for organising materials on the nanoscale. Examples include the work at the Naval Research Laboratory in Washington, D.C., using Cowpea mosaic virus (CPMV) particles to amplify signals in DNA microarray based sensors. In this application, the virus particles separate the fluorescent dyes used for signalling to prevent the formation of non-fluorescent dimers that act as quenchers.[225] Another example is the use of CPMV as a nanoscale breadboard for molecular electronics.[226]

Synthetic viruses

[edit]

Many viruses can be synthesised de novo ("from scratch"). The first synthetic virus was created in 2002.[227] Although somewhat of a misconception, it is not the actual virus that is synthesised, but rather its DNA genome (in case of a DNA virus), or a cDNA copy of its genome (in case of RNA viruses). For many virus families the naked synthetic DNA or RNA (once enzymatically converted back from the synthetic cDNA) is infectious when introduced into a cell. That is, they contain all the necessary information to produce new viruses. This technology is now being used to investigate novel vaccine strategies.[228] The ability to synthesise viruses has far-reaching consequences, since viruses can no longer be regarded as extinct, as long as the information of their genome sequence is known and permissive cells are available. As of June 2021, the full-length genome sequences of 11,464 different viruses, including smallpox, are publicly available in an online database maintained by the National Institutes of Health.[229]

Weapons

[edit]

The ability of viruses to cause devastating epidemics in human societies has led to the concern that viruses could be weaponised for biological warfare. Further concern was raised by the successful recreation of the infamous 1918 influenza virus in a laboratory.[230] The smallpox virus devastated numerous societies throughout history before its eradication. There are only two centres in the world authorised by the WHO to keep stocks of smallpox virus: the State Research Center of Virology and Biotechnology VECTOR in Russia and the Centers for Disease Control and Prevention in the United States.[231] It may be used as a weapon,[231] as the vaccine for smallpox sometimes had severe side-effects, it is no longer used routinely in any country. Thus, much of the modern human population has almost no established resistance to smallpox and would be vulnerable to the virus.[231]

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia
from Grokipedia
A virus is an acellular infectious agent consisting of a nucleic acid genome—either DNA or RNA—enclosed by a protective protein coat known as a capsid, with some possessing an additional lipid envelope derived from the host cell. These entities range in size from approximately 16 nm to over 300 nm (0.02–0.3 μm), much smaller than bacteria (typically 0.5–5 μm), and function as obligate intracellular parasites, incapable of independent replication or metabolism, requiring invasion and exploitation of host cellular machinery to propagate. Viruses infect diverse hosts across all domains of life, including bacteria (via bacteriophages), archaea, plants, and animals, often leading to cell lysis or persistent infections that drive significant evolutionary pressures through mechanisms like horizontal gene transfer. Lacking ribosomes, independent energy production, and growth capabilities, viruses fail to satisfy standard biological criteria for , positioning them as non-living replicators in , though debates persist regarding their borderline status due to evolutionary adaptability and genetic complexity. Their replication cycle typically involves attachment to host receptors, genome injection or , transcription and using host resources, assembly of new virions, and release via or , enabling rapid rates that facilitate antigenic drift and host . While notorious for causing acute and chronic diseases—exemplified by , , and emerging pandemics—viruses also underpin biotechnological advances, such as viral vectors in gene therapy and against antibiotic-resistant bacteria. Virus classification, notably the Baltimore system, delineates seven groups based on genome type (positive/negative-sense , double/single-stranded DNA/RNA) and mRNA synthesis mechanisms, reflecting their structural and replicative diversity from simple helical forms like to enveloped icosahedral structures like coronaviruses. Evolutionarily, viruses likely originated as escaped genetic elements or reduced cellular parasites, profoundly shaping host genomes—up to 45% of the bears viral remnants—and through gene shuffling, though their precise phylogenetic placement remains unresolved absent a universal . Controversies include underestimation of viral contributions to non-pathogenic ecological roles and overreliance on cell-culture models that may bias perceptions of infectivity, underscoring the need for empirical, host-contextual studies over institutionalized narratives.

History

Etymology

The word virus derives from Latin vīrus, signifying "poison," "sap of plants," or "slimy liquid." This term traces to Proto-Italic *weis-o-(s-), denoting poison, with possible cognates in Old Church Slavonic višnja for cherry, potentially alluding to toxic fruits. In English, virus first appears in the late 14th century, borrowed directly from Latin to describe a poisonous substance, as evidenced in translations like John Trevisa's Bartholomaeus Anglicus (c. 1398). By the 1590s, it extended to "venomous exudation from a living body," and by 1798, metaphorically to an agent causing infectious disease. The modern scientific usage for submicroscopic pathogens causing infection dates to 1883, coinciding with microbiological advances identifying filterable agents beyond bacteria. This shift retained the connotation of a noxious, invisible toxin, aligning with empirical observations of contagion without visible organisms.

Early Observations

In 1892, Russian microbiologist Dmitri Ivanovsky conducted filtration experiments on tobacco plants affected by mosaic disease, a condition first described by Adolf Mayer in 1879. Using Chamberland porcelain filters with pores small enough to retain , Ivanovsky found that the filtered sap from diseased leaves remained infectious when applied to healthy plants, indicating the presence of an ultrafilterable agent smaller than known . Ivanovsky initially interpreted this as evidence of a bacterial or dissolved enzymatic substance rather than a discrete living , as the agent did not form visible colonies in culture media. These findings challenged the prevailing germ theory, which attributed infectious diseases primarily to cultivable bacteria as demonstrated by Robert Koch's postulates in the 1880s. In 1898, Dutch microbiologist Martinus Beijerinck replicated and extended Ivanovsky's work, confirming the filterable nature of the tobacco mosaic agent through serial dilutions and passage experiments that showed progressive dilution reduced infectivity predictably, inconsistent with toxin persistence. Beijerinck proposed the term contagium vivum fluidum ("contagious living fluid") to describe a self-replicating, non-cellular entity that multiplied only within living host cells and could not be grown independently, distinguishing it from bacteria and laying foundational concepts for virology. Concurrently in 1898, German scientists Friedrich Loeffler and Paul Frosch reported similar filtration results for in , the first such observation in animals. Their experiments demonstrated that the infectious agent passed through bacteria-retaining filters and required living host tissue for propagation, extending the filterable agent paradigm beyond plants. These early observations collectively established that certain s were caused by submicroscopic, filter-passing pathogens—later termed viruses—incapable of independent or growth, prompting a reevaluation of infectious disease causation.

Scientific Discovery

In 1892, Russian biologist Dmitri Ivanovsky investigated tobacco mosaic disease by filtering sap from infected plants through porcelain Chamberland filters designed to retain ; the filtrate remained infectious upon to healthy plants, indicating the causal agent was smaller than known or possibly a . Ivanovsky initially favored a toxin hypothesis but noted the agent's persistence and infectivity, marking the first experimental evidence of a filterable . In 1898, Dutch microbiologist replicated Ivanovsky's experiments and demonstrated that the infectious agent multiplied exponentially in host tissues, diluting and re-concentrating in a manner inconsistent with a static ; he termed it contagium vivum fluidum, a self-replicating, fluid infectious principle that required living host cells for propagation, distinguishing it from . That same year, German scientists Friedrich Loeffler and Paul Frosch applied to in , identifying the first animal virus and showing it could be transmitted via filtered lymph, extending the concept beyond . Advances in shifted viruses from abstract entities to tangible macromolecules. In 1935, American biochemist Wendell Stanley isolated and crystallized (TMV) as a , demonstrating that purified crystals retained infectivity after redissolution, challenging views of viruses as merely fluids and highlighting their molecular nature akin to enzymes yet capable of . Direct visualization emerged with electron microscopy in the late 1930s; in 1939, Helmut Ruska and colleagues imaged TMV particles as rod-shaped structures approximately 300 nm long, confirming their particulate form and submicroscopic size, while 1940 micrographs of bacteriophages revealed tadpole-like morphologies attached to . These observations solidified viruses as discrete, obligate intracellular parasites, paving the way for as a distinct field.

Hypotheses on Viral Origins

The origins of viruses remain unresolved, with three principal hypotheses proposed based on , evolutionary modeling, and inferences from strategies. These include the progressive (or escape) hypothesis, the regressive (or reduction) hypothesis, and the virus-first (or co-evolution) hypothesis. is indirect, derived primarily from viral genome sequences showing mosaics of cellular-like and unique genes, alongside the absence of viral fossils predating cellular around 3.5–4 billion years ago. No single hypothesis accounts for the diversity of viral forms, including RNA viruses with high mutation rates and large DNA viruses encoding hundreds of proteins. The progressive hypothesis posits that viruses evolved from intragenomic elements, such as plasmids, transposons, or fragments, that acquired proteins and egress mechanisms, enabling autonomous transmission between cells. This scenario is supported by the similarity of some viral genes to host mobile elements and the observed integration of viral sequences into eukaryotic genomes, suggesting repeated "escapes" over evolutionary time. For instance, retroviruses like derive from endogenous retroviral elements comprising up to 8% of the , illustrating how genetic parasites can gain extracellular mobility. Critics note that this does not fully explain viruses lacking clear cellular homologs, such as those with unique polymerases. Conversely, the regressive hypothesis argues that viruses arose from free-living or parasitic cellular organisms, such as ancient or intracellular symbionts, that progressively lost metabolic genes through reductive while retaining replication machinery dependent on host cells. Evidence includes giant viruses like , discovered in 2003, which encode over 900 genes—including translation components—exceeding those of some unicellular parasites like Rickettsia, and exhibit host ranges akin to bacterial endosymbionts. This hypothesis aligns with observations of obligate intracellular undergoing genome shrinkage, from millions to hundreds of base pairs, paralleling viral minimalism. However, it struggles with the antiquity implied, as viral diversification appears to postdate major cellular domains. The virus-first hypothesis maintains that viruses or virus-like replicators predated or co-evolved alongside the first cells, originating from primordial RNA-protein complexes in a pre-cellular milieu, potentially seeding cellular genomes via gene transfer. Proponents cite the RNA world's reliance on self-replicating ribozymes, mirrored in simple RNA viruses like picornaviruses with genomes under 10 kb, and the ubiquity of viral genes in cellular proteomes—up to 10–20% in some estimates from horizontal transfers. Félix d'Herelle proposed an early version in the 1920s, suggesting viruses as autonomous precursors to cellular life. Challenges include explaining DNA viruses' complexity and the lack of evidence for non-parasitic ancient viruses, as all known viruses require cells for propagation. Phylogenetic reconstructions indicate polyphyletic origins, with RNA viruses possibly tracing to early RNA-world escapes and DNA viruses to later cellular reductions, reflecting multiple independent emergences rather than a monophyletic event. Ongoing metagenomic surveys, sequencing billions of viral particles from environments like oceans, continue to reveal novel lineages, underscoring the hypotheses' provisional nature amid incomplete sampling of virospheres estimated at 10^31 particles globally.

Biological Characteristics

Debate on Viral Life Status

The classification of viruses as living or non-living entities remains unresolved in , primarily due to ambiguities in defining itself. Traditional criteria for , such as those outlined by sources including cellular , independent , , growth, and autonomous , are frequently invoked; viruses fail most of these, as they consist of acellular particles (virions) lacking ribosomes, enzymes for production, or self-maintenance capabilities outside a host cell. Extracellular virions exhibit no metabolic activity and cannot replicate without hijacking host cellular machinery, positioning them as inert genetic packages rather than self-sustaining systems. Proponents arguing against viral life status emphasize obligate : viruses depend entirely on host cells for protein synthesis, , and replication, rendering them incapable of independent Darwinian in the strict sense required by definitions like NASA's—a self-sustaining chemical capable of undergoing —which viruses approximate only through host-mediated processes. This view aligns with the International Committee on Taxonomy of Viruses (ICTV), which treats viruses as distinct from cellular forms without ascribing to them. Critics of equating viruses with note that such claims often stem from metaphorical extensions of replication, ignoring the causal dependency on host biochemistry, where the virus directs but does not originate the processes. Conversely, advocates for considering viruses alive highlight their genetic complexity, capacity for mutation and natural selection, and shared molecular building blocks (DNA or RNA encased in protein) with cellular organisms, suggesting they represent a primitive or derived form of life. Some researchers propose the "virocell" concept, wherein an infected host cell transforms into a viral factory, effectively creating a novel living entity with emergent properties like replication and evolvability that transcend the inert virion state. Evolutionary analyses indicate viruses co-evolved with hosts, sharing ancient genes and driving biodiversity, which blurs boundaries and challenges rigid dichotomies. However, these arguments are contested for conflating host-virus dynamics with intrinsic vitality, as the virus alone cannot initiate or sustain these traits without external cellular infrastructure. No exists, with most defaulting to non-living status based on empirical failure to meet core life criteria, though the debate persists due to definitional fluidity and viruses' role in . Virologists like Eugene Koonin argue the question holds little substantive value for research, as viruses function as replicators regardless of categorical labels, prioritizing operational over philosophical . This ambiguity underscores causal realism in : viruses exert profound effects on through genetic hijacking, yet their inert extraceullar form precludes independent agency.

Structural Components

Viruses possess a basic structure comprising a genome encased in a protective protein shell known as the , which together form the nucleocapsid core of the virion. The serves to shield the genome from environmental damage and facilitates host cell attachment and entry. In non-enveloped viruses, the constitutes the outermost layer, while enveloped viruses acquire an additional membrane surrounding the nucleocapsid. The is assembled from repeating structural units called capsomeres, each composed of one or more protein subunits termed protomers. architectures exhibit three primary symmetries: helical symmetry, seen in elongated viruses such as where proteins coil around the ; icosahedral symmetry, approximating a 20-sided in spherical viruses like adenoviruses, optimizing enclosure with minimal protein; and complex symmetry, featuring additional structures like tails in bacteriophages such as T4, which include base plates and fibers for host recognition. These symmetries determine virion morphology, with icosahedral capsids often achieving T-numbers (e.g., T=1 for simplest, up to T=25 or higher in larger viruses) that dictate subunit count and stability. Enveloped viruses derive their lipid from modified host cell membranes during , incorporating viral glycoproteins that project as spikes for receptor binding and fusion. Underlying the , a matrix protein layer may stabilize the structure and link it to the nucleocapsid, as in influenza viruses where M1 protein regulates assembly. Some viruses include internal components like polymerases within the for immediate replication upon entry, though these are not universal. Virion sizes vary from 20 nm for viruses like picornaviruses to over 300 nm for complex poxviruses, reflecting structural diversity.

Genetic Material and Genome Features

Viruses contain genetic material composed of either DNA or RNA, which serves as the blueprint for viral replication and protein synthesis. This nucleic acid can be single-stranded (ss) or double-stranded (ds), linear or circular, and in some cases segmented into multiple molecules. Unlike cellular organisms, which universally employ dsDNA, viral genomes exhibit this diversity to adapt to host replication machinery and evade defenses. Viral genome sizes span several orders of magnitude, from under 3 kilobases (kb) in small ssDNA viruses such as geminiviruses (approximately 2,580 ) to over 2 megabases (Mb) in giant dsDNA viruses like pandoraviruses (around 2.5 Mb encoding nearly 2,500 proteins). Typical non-giant viral genomes range from 7 to 20 kb, with parvoviruses featuring 4–6 kb ss linear DNA and mimiviruses possessing 1.2 Mb dsDNA. This variation correlates with size and gene count, from a few genes in minimal viruses to hundreds in larger ones, though even giants encode fewer proteins than the smallest cellular genomes. Key features of viral genomes include extreme compactness, with high gene density and frequent overlapping genes, where the same nucleotide sequence encodes multiple proteins in different reading frames to maximize coding efficiency within size limits. RNA viruses often produce polyproteins that are cleaved post-translationally, while both DNA and RNA genomes generally lack introns and extensive non-coding regions. Mutation rates are elevated compared to cellular life, particularly in RNA viruses at approximately 10^{-4} substitutions per nucleotide per replication cycle due to error-prone polymerases, fostering rapid evolution; DNA viruses mutate more slowly, leveraging host proofreading enzymes. These traits enable viruses to exploit host resources while maintaining minimal self-sufficiency.

Host Dependency and Range

Viruses are intracellular parasites, incapable of independent replication due to the absence of ribosomes, metabolic enzymes, and energy production mechanisms, necessitating hijacking of host cellular machinery for duplication, protein synthesis, and virion assembly. This dependency confines viral to viable host cells, where the virus directs host ribosomes to translate viral and commandeers pools and polymerases for replication. Outside hosts, viruses persist as inert particles, resistant to environmental stresses but unable to propagate without cellular invasion. The host range of a virus encompasses the spectrum of susceptible , cell types, or strains it can infect, primarily dictated by molecular compatibility at entry points such as receptor-binding specificity of viral surface proteins to host glycoproteins or receptors. Intracellular barriers further restrict range, including uncoating efficiency, exploitation of host replication factors, and circumvention of antiviral defenses like responses or restriction factors. For A viruses, host specificity arises from adaptations to receptor linkages varying across —alpha-2,6 in humans versus alpha-2,3 in birds—enabling avian strains to occasionally adapt for mammalian transmission. Viruses display diverse host ranges, from highly narrow to exceptionally broad, influencing transmission dynamics and zoonotic potential. Narrow-range examples include infectious hematopoietic necrosis virus (IHNV), confined to salmonid species, reflecting stringent receptor and replication compatibilities. Conversely, infects over 1,200 plant species across multiple families, underscoring broad receptor promiscuity and metabolic adaptability in botanical hosts. demonstrates intermediate breadth, productively infecting primates, felines, mustelids, and suids via (ACE2) receptor variations, though inefficiently in without adaptation. Bacteriophages typically exhibit strain-specific narrow ranges within bacterial genera, though selection on diverse hosts can yield broader variants capable of lysing multiple strains. Host range expansions often occur via mutations altering attachment proteins or recombination with co-infecting viruses, as seen in historical pandemics originating from avian reservoirs adapting to human cells. Such shifts underscore causal links between ecological interfaces—like wildlife-livestock interfaces—and emergence risks, with empirical surveillance data revealing most human viruses derive from animal origins. Tissue tropism within permissive hosts adds granularity, where viruses like target neuronal subsets via specific receptor distributions, amplifying pathogenicity despite broader cellular susceptibility .

Replication and Dynamics

Infection Mechanisms

Viruses initiate infection by attaching to specific receptors on the host cell surface, a process mediated by interactions between viral surface proteins—such as glycoproteins on enveloped viruses or proteins on non-enveloped viruses—and host cell molecules including proteins, carbohydrates, or . This receptor binding determines viral host range and tropism, as the availability of compatible receptors dictates susceptible cell types; for instance, human immunodeficiency virus (HIV) targets receptors on T cells, while binds residues. Attachment often induces conformational changes in viral proteins, priming the virion for subsequent entry steps, and may involve co-receptors or accessory molecules to enhance specificity and efficiency. Following attachment, viral entry occurs via distinct pathways tailored to the virus structure and host. Enveloped viruses frequently employ direct fusion at the plasma membrane, where viral fusion proteins (e.g., in ) undergo pH-independent or receptor-triggered rearrangements to merge the with the host , releasing the into the . Alternatively, many enveloped viruses, such as and , enter through , where receptor-bound virions are internalized into s; low pH or proteolytic cleavage in the then activates fusion proteins to breach the endosomal . Non-enveloped viruses, lacking a , typically rely on endocytic uptake—via clathrin-coated pits, caveolae, or macropinocytosis—followed by endosomal escape through disassembly, pore formation, or penetration by viral peptides, as seen in adenoviruses utilizing protein VI for . Bacteriophages, which infect bacterial hosts, often bypass altogether, injecting directly through the and membrane via a tail fiber-mediated attachment and syringe-like apparatus, as exemplified by T4 phage piercing layers. These mechanisms exploit host cellular machinery while evading innate defenses like or receptor downregulation, though efficiency varies; for example, receptor density influences infection rates, with low-affinity bindings requiring higher viral titers. Entry failures, due to mismatched receptors or host restrictions, underpin viral specificity and inform antiviral strategies targeting these initial steps.

Replication Cycle

Viruses, lacking independent metabolic machinery, replicate solely within host cells by commandeering cellular ribosomes, enzymes, and energy sources for duplication and protein synthesis. The standard replication cycle encompasses attachment, penetration, uncoating, replication, assembly, maturation, and release, though specifics vary by viral family. Attachment initiates the cycle as viral capsid or glycoproteins bind to specific host cell surface receptors, conferring and host range. Penetration ensues via , direct membrane fusion for enveloped viruses, or nucleic acid injection as in bacteriophages. Uncoating follows, wherein host or viral proteases dismantle the capsid, liberating the into the or nucleus. Replication phase exploits host machinery: DNA viruses typically transcribe mRNA and replicate in the nucleus using cellular polymerases, while RNA viruses often operate cytoplasmically, with positive-sense serving directly as mRNA and negative-sense requiring viral . Retroviruses like reverse-transcribe to DNA for nuclear integration. Viral proteins, including structural components, are translated on host ribosomes. Assembly packages replicated genomes with synthesized proteins into progeny virions, often self-assembling spontaneously; maturation may involve proteolytic cleavage for infectivity. Release disperses virions: non-enveloped viruses via host cell lysis in the lytic cycle, or enveloped ones through budding, acquiring lipid envelopes from host membranes without immediate lysis. Bacteriophages exhibit lytic cycles culminating in host lysis or lysogenic cycles integrating phage DNA as into bacterial , replicating passively during until environmental cues trigger lytic induction. Analogous latency occurs in eukaryotic viruses like herpesviruses, evading immunity via genome persistence without active production.

Genetic Variation and Evolution

Viruses exhibit high rates of genetic variation due to error-prone replication mechanisms, enabling rapid evolution in response to selective pressures such as host immunity and antiviral therapies. Mutation rates in RNA viruses typically range from 10^{-6} to 10^{-4} substitutions per nucleotide per replication cycle, orders of magnitude higher than the 10^{-8} to 10^{-6} observed in DNA viruses, primarily because most RNA-dependent RNA polymerases lack 3'–5' exonuclease proofreading activity. DNA viruses, by contrast, often benefit from host cellular proofreading enzymes during replication, resulting in lower fidelity errors. These elevated mutation frequencies, combined with short generation times and large population sizes within hosts, generate substantial genetic diversity per infection cycle. Beyond point mutations, viruses diversify through recombination—exchange of genetic segments between co-infecting strains—and reassortment in segmented genomes, where entire segments are swapped. Recombination occurs via template switching during replication or breakage and rejoining of nucleic acids, prevalent in RNA viruses like coronaviruses and retroviruses. Reassortment, unique to viruses with multipartite genomes such as , allows rapid assembly of novel combinations from parental strains in doubly infected cells, facilitating jumps to new hosts or evasion of immunity. These processes amplify variation beyond mutation alone, with favoring fit variants amid and bottlenecks during transmission. The quasispecies model describes viral populations as dynamic clouds of closely related mutants rather than uniform clones, arising from mutation rates exceeding the error threshold for consensus sequence maintenance. In this framework, intra-host diversity enables collective adaptation, with defective genomes potentially complementing fit ones, though selection prunes deleterious variants over time. RNA viruses like poliovirus exemplify this, maintaining mutant swarms that enhance adaptability to environmental stresses. Evolutionary rates vary widely, with substitution rates spanning six orders of magnitude influenced by genomic architecture, replication speed, and selection intensity rather than alone. For instance, -1, an RNA , accumulates substitutions at approximately 10^{-3} per site per year, driven by errors and recombination, enabling immune escape and . A undergoes antigenic drift via gradual mutations in and neuraminidase genes, necessitating annual updates, while major shifts from reassortment caused pandemics like 1957 (H2N2) and 1968 (H3N2). evolves more slowly than or , with a rate of about 10^{-3} substitutions per site per year, yet variants like (B.1.1.529, detected November 2021) emerged through recombination and selection for transmissibility and immune evasion. These patterns underscore viruses' capacity for adaptive evolution, constrained by host factors and transmission dynamics.

Persistent and Latent Infections

Persistent infections occur when a virus establishes long-term presence in the host without complete clearance, often involving continuous or intermittent replication at low levels that avoids rapid host cell destruction or immune elimination. These infections contrast with acute ones by persisting beyond the initial symptomatic phase, typically through mechanisms such as antigenic variation, downregulation of viral , or integration into the host genome, allowing the virus to evade adaptive immunity while maintaining in reservoirs like lymphocytes or epithelial cells. Host factors, including immune suppression or genetic predispositions, contribute to persistence, as seen in cases where defective immune responses fail to eliminate infected cells. Latent infections represent a of persistent infections characterized by the viral genome's dormancy within host cells, with minimal or no production and no active replication, enabling indefinite survival without immediate . Latency is maintained by epigenetic silencing of viral promoters, such as modifications or interference, which repress lytic genes while preserving the in episomal or integrated forms, often in non-dividing cells like neurons. Reactivation can be triggered by stressors like , hormonal changes, or UV exposure, shifting to productive replication and shedding. This strategy ensures viral propagation through asymptomatic carriers, as the latent phase imposes no fitness cost on the host until reactivation. Mechanisms distinguishing persistent from strictly latent infections include ongoing low-level virion production in the former, which sustains chronic inflammation or immune exhaustion, versus transcriptional quiescence in latency that permits without constant exposure. For instance, in persistent infections like (HBV), the virus replicates in hepatocytes via reverse transcription of pregenomic , leading to circulating Dane particles and immune complex-mediated liver damage over decades. In contrast, herpes simplex virus type 1 (HSV-1) establishes latency in trigeminal ganglia, where the genome circularizes as an with only latency-associated transcripts (LATs) expressed, suppressing immediate-early genes until neuronal stress induces lytic reactivation, causing recurrent oral lesions in approximately 20-40% of carriers annually. Human immunodeficiency virus (HIV) exemplifies a hybrid persistent infection with latent reservoirs in resting CD4+ T cells, where integrated proviral DNA remains transcriptionally silent due to compaction, resisting antiretroviral therapy and contributing to rebound upon treatment cessation. These dynamics highlight how viruses exploit host cellular machinery for survival, often leading to lifelong carriage and potential oncogenic risks, as in Epstein-Barr virus latency linked to Burkitt's via restricted in B lymphocytes. Persistent and latent infections pose challenges for eradication, as antiviral drugs targeting replication fail against dormant genomes, necessitating strategies like latency-reversing agents to expose hidden reservoirs for immune clearance. Examples include varicella-zoster virus (VZV), which after primary integrates latently in dorsal root ganglia and reactivates as in 30% of infected individuals over age 80 due to waning . Such infections underscore viral adaptation to host longevity, prioritizing transmission over in stable populations.

Classification

ICTV Taxonomic Framework

The International Committee on Taxonomy of Viruses (ICTV), established in 1971 under the International Union of Microbiological Societies, serves as the authoritative body for naming and classifying viruses and virus-like entities worldwide. It maintains a universal taxonomy based on shared properties, evolutionary relationships, and genetic characteristics, distinguishing viruses as physical entities from the abstract taxa to which they are assigned. This framework excludes viruses from the of cellular life (, , Eukarya), instead employing a dedicated hierarchy that begins at the rank of to accommodate viral diversity. The ICTV taxonomy utilizes up to 15 hierarchical ranks, expanded from five traditional levels (order, , , , ) in to better align with Linnaean principles while partitioning the virosphere into discrete groups. These ranks, in descending order of inclusivity, are: , subrealm, kingdom, subkingdom, , , class, subclass, order, suborder, , , , subgenus, and . Classification decisions are guided by empirical data on virion morphology, genome type and , replication , and phylogenetic analyses, with proposals ratified by ICTV executive and votes. As of the August 2025 release (following 2025 ratifications under Master Species List #40), the taxonomy encompasses 7 , 11 kingdoms, 22 , 4 , 49 classes, 93 orders, 12 suborders, over 800 , and thousands of , reflecting ongoing discoveries in viral . Key realms include Adnaviria (featuring linear double-stranded DNA in A-form conformation, infecting archaea and bacteria), Duplodnaviria (double-stranded DNA viruses with diverse hosts, including bacteriophages), Monodnaviria (monopartite single-stranded DNA viruses), Riboviria (RNA viruses using RNA-dependent RNA polymerase), Ribozyviria (ribozyme-based replication in viroids and relatives), Shotokuvirae (segmented RNA viruses), and Varidnaviria (vertically transmitted DNA viruses with icosahedral symmetry). These higher ranks group viruses by fundamental replication mechanisms and genome architectures, with lower ranks refining based on host range, protein homology, and sequence divergence. Recent updates, such as standardized binomial species names (genus epithet plus descriptive term), enhance precision and interoperability with genomic databases. The framework evolves through proposal-based amendments, prioritizing and diagnostic traits over host specificity alone, though debates persist on accommodating uncultured viruses identified via . ICTV resources, including the online browser and annual reports, provide searchable access to ratified classifications, ensuring the system's adaptability to new data without retroactive overhauls. This structure underpins virological by offering a stable, evidence-driven that facilitates cross-study comparisons.

Baltimore Classification System

The Baltimore classification system, proposed by virologist in 1971, divides viruses into seven groups based on the type of in their and the specific pathway used to synthesize (mRNA) from that . This functional scheme focuses on the —particularly the flow of genetic information from to mRNA—rather than morphological or host-range criteria, providing a framework that highlights diverse replication strategies among viruses. Baltimore's original publication outlined six classes, with the seventh added later to accommodate viruses that use despite possessing a partially double-stranded DNA . Viruses in Group I contain double-stranded DNA (dsDNA) genomes and produce mRNA via host transcription, similar to cellular DNA. Examples include adenoviruses, herpesviruses, and poxviruses. Group II viruses have single-stranded DNA (ssDNA) genomes, which are converted to dsDNA intermediates before transcription to mRNA; parvoviruses exemplify this group. Group III features double-stranded (dsRNA) genomes, where viral transcribes mRNA from one strand; reoviruses are representative. Group IV viruses possess positive-sense single-stranded (+ssRNA) genomes that function directly as mRNA upon entry into the host cell, enabling immediate translation; picornaviruses and coronaviruses belong here. In contrast, Group V viruses have negative-sense single-stranded (-ssRNA) genomes requiring transcription by viral to generate +mRNA; examples include rhabdoviruses (e.g., ) and paramyxoviruses (e.g., virus). Group VI comprises retroviruses with +ssRNA genomes that are reverse-transcribed into DNA, which integrates into the host genome for subsequent mRNA production; human immunodeficiency virus () is a key example. Group VII includes viruses with partially dsDNA genomes that replicate via an RNA intermediate using , such as hepadnaviruses like . This classification remains influential for understanding viral gene expression and has informed antiviral drug development by targeting group-specific enzymes, like inhibitors for Groups VI and VII. While orthogonal to the International Committee on Taxonomy of Viruses (ICTV) hierarchy, it complements taxonomic efforts by emphasizing mechanistic differences.
GroupGenome TypemRNA Synthesis MechanismExamples
IdsDNADirect transcription by host Adenoviruses, herpesviruses, poxviruses
IIssDNAConversion to dsDNA, then transcriptionParvoviruses
IIIdsRNATranscription by viral RdRp from dsRNA templateReoviruses
IV+ssRNAGenome serves as mRNAPicornaviruses, coronaviruses
V-ssRNATranscription by viral RdRp to +mRNARhabdoviruses, paramyxoviruses
VI+ssRNA-RTReverse transcription to DNA, integration, then transcriptionRetroviruses (e.g., )
VIIdsDNA-RTRNA intermediate via reverse transcription for replicationHepadnaviruses (e.g., )
RdRp: RNA-dependent RNA polymerase

Phylogenetic and Functional Classifications

Phylogenetic classification of viruses employs molecular sequence data, primarily from conserved genes, to reconstruct evolutionary relationships via phylogenetic trees. These trees are generated using methods such as maximum likelihood or Bayesian inference on aligned nucleotide or amino acid sequences, revealing monophyletic clades that underpin taxonomic ranks like genera and species. For RNA viruses, the RNA-dependent RNA polymerase (RdRp) gene serves as a key marker due to its universal presence and moderate conservation across diverse lineages, enabling delineation of higher-order groups such as realms in the ICTV system. Similarly, DNA viruses often rely on DNA polymerase or major capsid protein sequences for phylogeny, as demonstrated in analyses of tailed bacteriophages where capsid genes support hierarchical clustering aligned with host specificity and genome organization. This approach has resolved debates over polyphyly in groups like double-stranded DNA viruses, confirming their integration into the broader tree of life through traceable genomic ancestries. The ICTV taxonomic framework increasingly prioritizes phylogenetic , with updates as of 2023 visualizing classifications as ranked pyramids mapped onto trees to accommodate signatures that challenge strict branching patterns. For prokaryotic viruses, tools apply pairwise genetic distances and branch support metrics to propose ranks consistent with , outperforming phenotype-only schemes in resolving fine-scale diversity. In human pathogens like , complete genome phylogenies provide superior resolution over partial genes, informing sub-lineage nomenclature with genetic distances below 2% defining boundaries. Challenges persist for highly mutable viruses, where recombination and reassortment necessitate multi-locus analyses to avoid artefactual topologies. Functional classifications group viruses by operational traits and biological mechanisms, independent of strict phylogeny, to emphasize adaptive strategies and host interactions. These include distinctions between lytic viruses, which destroy host cells upon replication, and lysogenic ones, which integrate into host genomes for dormant propagation, as seen in temperate bacteriophages. Viruses are further stratified by envelope presence, which correlates with transmission modes and immune evasion—enveloped forms acquire host lipids for stability in extracellular environments, while non-enveloped rely on robust capsids for fecal-oral spread. Oncogenic potential represents another functional axis, where viruses like certain papillomaviruses induce tumors via protein-host interactions disrupting controls, a trait convergent across unrelated lineages due to shared selective pressures rather than . Such schemes complement phylogenetic data by highlighting , as functional convergence in replication efficiency or host range can unite distantly related viruses in ecological guilds, though they risk oversimplification without genetic validation.

Ecological and Evolutionary Roles

In Ecosystems

Viruses are among the most abundant biological entities in ecosystems, with global estimates indicating approximately 10^{30} viral particles in the alone. In marine environments, concentrations typically range from 10^6 to 10^8 viruses per milliliter of , surpassing bacterial abundances by an . In terrestrial soils, viral densities reach 10^8 to 10^9 particles per gram, particularly in organic-rich, moist conditions. These high numbers position viruses as key regulators of microbial dynamics across habitats. Bacteriophages, which target prokaryotes, exert top-down control on microbial populations by lysing infected cells, thereby curbing bacterial overgrowth and fostering community diversity. This predation prevents by dominant , as evidenced in studies of outbreaks where phage activity shifted bacterial compositions. In microbial communities, phages induce phenotypic heterogeneity, enhancing resilience through varied responses. Such interactions drive evolutionary pressures, including the Red Queen dynamics where hosts and viruses co-evolve, promoting genetic diversity. In aquatic ecosystems, the viral shunt mechanism redirects carbon flow by lysing microbes, converting into dissolved forms that remineralize, bypassing higher trophic levels. This process recycles a substantial fraction of —up to 30% in some models—into the , sustaining nutrient availability and influencing global biogeochemical cycles like . Viral activity thus modulates the efficiency of biological pumps in oceans, with implications for atmospheric CO_2 levels. Terrestrial ecosystems feature analogous roles, where soil viruses impact bacterial and decomposition processes. Phage lysis releases bioavailable nitrogen, enhancing plant productivity, while also disseminating genes via transduction, which accelerates adaptation in microbial consortia. In both realms, viruses bridge ecosystems by facilitating , including across environmental boundaries, underscoring their integral function in maintaining ecological balance and function.

Influence on Host Evolution

Viruses impose strong selective pressures on host populations by causing differential mortality and reproduction, favoring genetic variants that confer resistance or tolerance to infection. This coevolutionary drives the fixation of advantageous in host genomes, such as those enhancing immune responses or altering viral entry receptors. from both natural and experimental systems demonstrates that viral epidemics can rapidly shift allele frequencies, with host adaptations often arising from standing rather than new . A classic example is the between (MYXV) and European rabbits (Oryctolagus cuniculus) following the virus's introduction as a biocontrol agent in in 1950. Initially, the virus killed over 99% of infected rabbits, but within a decade, host survival rates increased to around 70-90% due to selection for genetic resistance traits, including enhanced innate immunity and reduced efficiency. Concurrently, the virus attenuated, with field isolates showing decreased to balance transmission and host killing. Parallel adaptations occurred independently in Australian, European, and Chilean rabbit populations, involving the same immune-related genes like those in the TLR2 pathway, underscoring the predictability of selection under viral pressure. Endogenous retroviruses (ERVs), ancient viral integrations into DNA, have profoundly shaped mammalian by providing novel genetic elements co-opted for host functions. Comprising up to 8-10% of the , ERVs contributed genes like , derived from HERV-W envelope proteins, which facilitate fusion essential for placental development in eutherian mammals—a trait absent in marsupials. This likely enabled evolutionary innovations in around 100-150 million years ago, with syncytin orthologs conserved across species but originating from independent retroviral captures. While most ERVs are silenced by host epigenetic mechanisms to prevent , their regulatory sequences influence , immunity, and development, demonstrating viruses' dual role as parasites and genetic innovators. In humans, the -Δ32 deletion allele, present in about 10% of Europeans (homozygosity ~1%), blocks -1 entry by truncating the coreceptor, conferring near-complete resistance to R5-tropic strains responsible for most infections. This mutation's recent origin (estimated 700-5,000 years ago) and clinal frequency gradient suggest positive selection by historical epidemics, potentially or (bubonic plague), as modulates inflammatory responses to these pathogens. Ongoing prevalence continues to exert pressure, maintaining the allele's advantage in high-risk populations, though homozygous carriers face no evident fitness costs in uninfected states. Such examples highlight how viruses not only select for defensive traits but can indirectly drive broader evolution.

Viral Diversity and Discovery

Viruses represent the most abundant biological entities on , with an estimated 10^{31} individual particles distributed across , soils, and hosts, vastly outnumbering stars in the . This abundance underscores their unparalleled diversity, encompassing genetic, structural, and host-range variations that infect , , eukaryotes, and even other viruses. While the International Committee on of Viruses (ICTV) has classified approximately 14,690 as of 2023, extrapolations suggest the global virome comprises 10^7 to 10^9 distinct , with over 1 million estimated in mammals alone. These figures highlight that classified viruses capture only a fraction of the virosphere, limited by sampling biases toward pathogenic or culturable strains. Early virus discovery relied on indirect evidence and rudimentary techniques. In 1892, Dmitri Ivanovsky demonstrated that tobacco mosaic disease passed through bacteria-retaining filters, indicating a sub-bacterial agent, later confirmed by in 1898 as a "contagium vivum fluidum." Bacteriophages were observed in 1915 by Frederick Twort and independently in 1917 by Félix d'Herelle, marking the first visualization of viral infection cycles via plaque assays on bacterial lawns. The , introduced in the 1930s, enabled direct imaging, revealing diverse morphologies like icosahedral and helical capsids, while methods in the 1940s–1950s facilitated isolation of animal viruses such as . These approaches, however, favored viruses that propagate in lab hosts, underestimating environmental and diversity. Modern discovery has shifted to culture-independent methods, particularly viral metagenomics using next-generation sequencing (NGS). Metagenomic surveys sequence total nucleic acids from environmental samples or host tissues, assembling viral genomes de novo without prior cultivation, uncovering novel families like giant viruses (e.g., mimiviruses) and viromes in uncultured niches. For instance, viromes reveal billions of phage types driving bacterial mortality, while mammalian studies estimate hundreds of thousands of undetected viruses via meta-transcriptomics. Bioinformatics pipelines filter host and bacterial sequences, identify viral hallmarks (e.g., genes), and classify via markers like , though challenges persist in distinguishing viable viruses from fragments and resolving incomplete assemblies. Discovery rates continue accelerating, with no in sight, implying ongoing expansions in known diversity through targeted sampling of underrepresented hosts like and protists.

Pathogenicity and Disease

Mechanisms of Disease Causation

Viruses cause disease through a series of interactions with host cells and tissues, beginning with attachment to specific cellular receptors that determine tissue tropism, followed by entry via endocytosis or membrane fusion, uncoating, and replication using hijacked host machinery. This replication disrupts normal cellular functions, often resulting in direct cytopathic effects (CPE) such as cell lysis, where virions bud or accumulate until the host cell membrane ruptures, releasing progeny viruses; apoptosis, triggered by viral proteins activating host caspases; syncytium formation, as seen in paramyxoviruses like measles where fusion proteins merge infected cells; or intracytoplasmic/nuclear inclusion bodies from aggregated viral components. For instance, enteroviruses like poliovirus induce CPE through phosphatidylinositol 4-kinase recruitment, altering membrane structure and leading to osmotic lysis in neurons. In cytopathic viruses such as influenza A or herpes simplex, CPE directly contributes to pathology by destroying epithelial cells in the respiratory tract or skin, respectively, impairing barrier function and causing localized inflammation. However, many viruses, including hepatitis B virus (HBV) and human immunodeficiency virus (HIV), exhibit minimal direct CPE and instead provoke disease via host immune responses. Cytotoxic CD8+ T cells target and lyse infected cells bearing viral antigens on MHC class I, which can amplify damage in tissues with high infection rates, as in HBV-induced chronic hepatitis where T-cell infiltration leads to hepatocyte necrosis and fibrosis. Immune-mediated mechanisms further include excessive cytokine production (e.g., interferon-gamma and tumor necrosis factor-alpha) during acute responses, culminating in "cytokine storms" that increase and recruit inflammatory cells, exacerbating tissue injury beyond —as observed in severe or cases. , where non-neutralizing antibodies facilitate viral entry into immune cells via Fc receptors, can intensify infection in dengue or certain coronaviruses. Additionally, persistent infections may cause chronic pathology through ongoing low-level replication and immune activation, leading to autoimmune-like responses or exhaustion, as in depleting + T cells indirectly via immune clearance. Unlike , viruses rarely produce exotoxins but may encode proteins mimicking toxins, such as HIV's Tat protein inducing via . Viral spread mechanisms amplify causation: primary disseminates virus hematogenously to target organs, while neurotropism via , as in , evades immunity to reach the . Host factors like age, genetics, and coinfections modulate severity; for example, neonates lack mature adaptive immunity, heightening susceptibility to disseminated . Empirical studies confirm these processes, with in vitro CPE assays correlating to in vivo , though immune contributions often predominate in resolving infections.

Human Viral Infections

Viruses cause a spectrum of infections in humans, ranging from self-limiting illnesses like the to chronic conditions and fatal diseases. Respiratory viruses predominate in acute infections, with influenza virus (IV) causing approximately 1 billion cases annually worldwide, including 3-5 million severe illnesses and 290,000-650,000 respiratory deaths. Respiratory syncytial virus (RSV) primarily affects infants and the elderly, leading to and , with global estimates of millions of lower respiratory infections yearly. Human coronaviruses, including responsible for , contribute to upper and lower respiratory diseases, with seasonal endemic strains causing common colds. Gastrointestinal viruses, such as noroviruses and rotaviruses, induce acute , particularly in children; was a leading cause of severe before widespread reduced hospitalizations by over 85% in vaccinated populations. Hepatic viruses like (HBV) and (HCV) establish chronic infections in millions, with HBV affecting 296 million people globally in 2019 and leading to or in 15-25% of chronic carriers without intervention. HCV chronically infects about 58 million worldwide, with 80% of cases progressing silently until advanced liver damage occurs. Herpesviruses, including herpes simplex viruses (HSV-1 and HSV-2), cytomegalovirus (CMV), and Epstein-Barr virus (EBV), often establish lifelong latency after primary infection. HSV-1 causes oral lesions in 67% of the global population under 50, while HSV-2 genital infections affect 13% of those aged 15-49. CMV infects over 50% of adults by age 40 in developed countries, typically asymptomatic but severe in immunocompromised individuals. EBV, linked to infectious mononucleosis, infects nearly 95% of adults worldwide and associates with certain lymphomas. Human immunodeficiency virus () targets CD4+ T cells, progressing to acquired immunodeficiency syndrome (AIDS) without treatment, with approximately 40.4 million deaths since its identification in 1983 and 39 million people living with in 2023. Transmission occurs primarily through blood, sexual contact, and perinatal routes. Emerging viral threats include virus disease (EBOD), with case fatality rates of 25-90% depending on strain and outbreak, as seen in the 2014-2016 claiming over 11,000 lives, and , which caused microcephaly in fetuses during the 2015-2016 outbreak. These zoonotic viruses highlight risks from wildlife interfaces, with ongoing surveillance needed due to sporadic reemergence.

Infections in Non-Human Hosts

Viruses infect prokaryotic hosts including and , with bacteriophages representing the most abundant biological entities on , estimated at over 10^31 particles globally. These viruses modulate bacterial communities by lysing host cells, altering abundance, diversity, , and , thereby influencing and dynamics such as transformation in soils. In marine and gut microbiomes, phages drive bacterial through and selection pressures, maintaining microbial balance and preventing dominance by any single . Viruses of archaea exhibit distinct morphologies, such as bottle-shaped or tailed forms, and similarly regulate archaeal populations in extreme environments like deep-sea vents, contributing to global biogeochemical processes. In animal hosts, viruses establish reservoirs that sustain transmission chains and pose zoonotic risks, with bats, , and birds exhibiting high viral diversity due to factors like flight-induced immune adaptations and social behaviors. Bats harbor a disproportionate share of zoonotic viruses, including coronaviruses like progenitors and filoviruses such as , often asymptomatically, with over 20 virus families detected in global surveys. carry pathogens like hantaviruses and arenaviruses, linked to outbreaks such as hemorrhagic fevers, while birds serve as amplifiers for viruses (e.g., H5N1), which circulate in wild populations and spill over to and mammals. Domestic animals, including , act as intermediate hosts or reservoirs for viruses like Nipah from bats via pigs, underscoring the role of wildlife-livestock interfaces in viral emergence. Plant viruses infect crops and wild , causing substantial agricultural losses estimated in billions annually through yield reductions and degradation. Examples include lethal necrosis , resulting from synergistic infections by maize chlorotic mottle virus and potyviruses, which devastated yields in starting around 2011. and related tobamoviruses persist in soil and on surfaces, transmitted mechanically or by , affecting solanaceous crops worldwide. Aphid-vectored viruses like those in the Luteoviridae family exacerbate damage by manipulating vector behavior to enhance transmission. In non-agricultural contexts, viruses influence weed dynamics and can cross-infect ornamentals, though systemic host defenses like silencing limit spread in some cases. Viruses also infect fungi (mycoviruses) and protists, though less studied than in other hosts. Mycoviruses often persist latently in fungal cells, modulating host virulence; for instance, certain reduce aggressiveness in plant-pathogenic fungi like Cryphonectria parasitica, aiding biological control efforts. viruses, including those of amoebae and , drive evolutionary pressures in aquatic microbial food webs, with giant viruses like mimiviruses infecting free-living amoebae and potentially influencing bacterial predation dynamics. These infections highlight viruses' universal role in regulating microbial and multicellular host populations across domains of life.

Oncogenic Potential

Certain viruses, known as oncoviruses, possess the capacity to transform host cells and initiate tumorigenesis, contributing to an estimated 12-15% of all human cancers globally based on epidemiological data linking viral infections to specific malignancies. This oncogenic potential arises not from viruses directly proliferating uncontrollably but from their disruption of cellular regulatory pathways, often requiring cofactors such as chronic inflammation, immunosuppression, or genetic predispositions. The International Agency for Research on Cancer (IARC) classifies seven viruses as carcinogens with sufficient evidence in humans: high-risk human papillomaviruses (HPVs), (HBV), (HCV), Epstein-Barr virus (EBV), human T-lymphotropic virus type 1 (HTLV-1), (KSHV or HHV-8), and (MCV). High-risk HPVs (types 16 and 18 primarily) drive approximately 5% of cancers worldwide, including nearly all cervical cancers, via integration into the host and expression of E6 and E7 oncoproteins that degrade and Rb tumor suppressors, respectively, thereby promoting uncontrolled cell proliferation. HBV and HCV account for over 75% of hepatocellular carcinomas, with HBV's DNA integrating into hepatocyte to activate proto-oncogenes like c-Myc while HCV's induces chronic and leading to and . EBV, linked to Burkitt's lymphoma, Hodgkin's lymphoma, and , encodes latent membrane proteins (LMP1) that mimic CD40 signaling to activate pathways, fostering B-cell immortalization and immune evasion. HTLV-1 causes adult T-cell /lymphoma in 2-5% of infected individuals through Tax protein-mediated transactivation of host genes and inhibition of ; KSHV promotes via LANA protein stabilizing hypoxia-inducible factors and ; MCV integrates into cells, expressing truncated T antigen that disrupts Rb and . Mechanisms of viral oncogenesis converge on common host pathways despite viral diversity: DNA viruses like HPV and HBV often integrate their genomes, causing or chronic antigen stimulation; RNA viruses like HCV and HTLV-1 trigger persistent via release and , accumulating somatic mutations over decades. Viral proteins frequently target regulators (e.g., homologs in EBV), epigenetic modifiers (e.g., deacetylases in KSHV), or , while immune suppression—seen in HIV-coinfected patients—exacerbates risk by impairing viral clearance. Empirical evidence includes reduced cancer incidence post-HPV vaccination (e.g., 90% drop in cervical precancers in vaccinated cohorts since 2006) and HBV vaccination programs halving rates in by 2010. Not all infections progress to cancer; latency, host (e.g., HLA alleles influencing EBV persistence), and environmental cofactors determine outcomes, underscoring multifactorial . In non-human hosts, analogous potentials exist, such as avian leukosis virus in chickens or mouse mammary tumor virus in rodents, but human data predominate due to extensive .

Prevention, Control, and Treatment

Host Defense Mechanisms

Host defense mechanisms against viruses encompass both innate and adaptive components that collectively detect, restrict, and eliminate viral pathogens. The provides rapid, non-specific responses through physical barriers and cellular sensors, while the adaptive system generates antigen-specific immunity for long-term protection. These mechanisms evolved to counter viral replication strategies, such as hijacking host machinery and evading detection, though viruses frequently deploy countermeasures like immune suppression or antigenic variation. Physical and chemical barriers form the first line of defense, including intact , mucosal linings, and secretions like in saliva and tears that degrade viral envelopes or capsids. Once breached, pattern recognition receptors (PRRs) on host cells detect viral pathogen-associated molecular patterns (PAMPs), such as double-stranded or unmethylated CpG DNA motifs. Cytosolic sensors like RIG-I-like receptors (RLRs) and endosomal Toll-like receptors (TLRs) trigger signaling cascades leading to production. Type I interferons (IFN-α and IFN-β), produced by infected cells, induce an antiviral state in neighboring uninfected cells by upregulating interferon-stimulated genes (ISGs). These ISGs encode proteins that inhibit viral processes, including R (PKR) which halts translation upon detecting dsRNA, and 2'-5'-oligoadenylate synthetase (OAS) which activates RNase L to degrade viral and host RNA. Type III interferons (IFN-λ) similarly restrict replication at epithelial barriers, while type II interferon (IFN-γ) enhances activation and MHC expression. and serve as cell-intrinsic defenses; sequesters viral components for lysosomal degradation, and eliminates infected cells to limit progeny virus release, though some viruses inhibit these pathways. Natural killer (NK) cells, part of the innate lymphoid compartment, rapidly target virus-infected cells displaying altered surface ligands or low MHC class I expression—a phenomenon known as "missing self" recognition. NK cells release perforin and granzymes to induce in targets, and produce cytokines like IFN-γ to amplify antiviral responses. In humans, NK cell activation during acute infections, such as with , can expand adaptive-like NK subsets with enhanced specificity via epigenetic imprinting. The adaptive immune response, bridging innate signals via antigen-presenting cells like dendritic cells, involves T and B lymphocytes. Cytotoxic + T cells recognize viral peptides presented on , lysing infected cells through Fas-FasL interactions or granule . Helper CD4+ T cells, via , coordinate responses by secreting cytokines that activate macrophages and promote differentiation. B cells produce neutralizing antibodies that bind free virions, preventing attachment to host receptors, or opsonize them for ; memory B and T cells confer lifelong immunity against reinfection, as evidenced by robust control of varicella-zoster virus post-primary exposure. In non-vertebrate hosts, (RNAi) provides a conserved antiviral mechanism, where processes viral double-stranded RNA into small interfering RNAs (siRNAs) that guide proteins to cleave complementary viral genomes. While prominent in and as the primary defense, RNAi contributes modestly in mammals, suppressed by robust pathways, though it restricts certain viruses like in interferon-deficient models.

Vaccine Development and Efficacy

Viral vaccine development employs diverse strategies to elicit protective immunity while minimizing disease risk, including live-attenuated vaccines that use weakened pathogen strains to mimic natural infection, as seen in the measles-mumps-rubella (MMR) vaccine developed in the 1960s and the oral polio vaccine (OPV) by Albert Sabin in 1961. Inactivated vaccines, which employ killed virus particles, underpin the inactivated polio vaccine (IPV) introduced by Jonas Salk in 1955 and seasonal influenza shots, offering safety for immunocompromised individuals but often requiring boosters due to humoral rather than cellular immunity dominance. Subunit and recombinant vaccines target specific antigens, such as the hepatitis B surface antigen produced via yeast expression since 1986, while newer platforms like viral vectors (e.g., adenovirus-based) and mRNA technologies enable rapid adaptation but face scalability and stability hurdles in production. Historical milestones include Edward Jenner's 1796 smallpox variolation precursor and Max Theiler's 1937 yellow fever vaccine, the first lab-attenuated viral vaccine, demonstrating serial passage in host cells to reduce virulence while preserving immunogenicity. Efficacy is quantified primarily through randomized controlled trials (RCTs) measuring , calculated as VE = (1 - [attack rate in vaccinated / attack rate in unvaccinated]) × 100%, with phase III trials assessing symptomatic prevention under controlled conditions. Observational studies post-licensure estimate real-world effectiveness against hospitalization or transmission, though these can be confounded by factors like prior exposure or strain matching. For stable viruses, efficacy exceeds 95%: the achieved global eradication by 1980 via thresholds above 80% coverage, while measles yielded over 92% case reductions pre-1980 and near-100% protection from two doses in trials, saving an estimated 56 million lives from 2000-2021 despite coverage gaps. vaccines reduced U.S. cases by over 99% post-1955, with OPV conferring mucosal immunity against fecal-oral spread but carrying rare reversion risks. vaccines, however, average 40-60% effectiveness annually due to antigenic mismatches from predictive strain selection, with 50% deemed successful amid rapid evolution. High mutation rates—up to 10^-3 to 10^-5 errors per per replication cycle—pose core challenges via antigenic drift (gradual changes) and shift (reassortment), necessitating universal vaccine designs targeting conserved regions like stalks. This variability explains waning protection in respiratory viruses, where escape mutants evade , as evidenced by annual reformulations failing to fully anticipate dominant strains, reducing against mismatched variants by up to 50%. Development pipelines incorporate preclinical animal models (e.g., ferrets for ) and correlates of protection like neutralizing titers, but translating these to humans remains imperfect, particularly for mucosally transmitted pathogens requiring T-cell responses over serum . Despite advances, no vaccines exist for highly mutable viruses like or , underscoring the causal primacy of viral genetic instability over host factors in limiting durable immunity.

Antiviral Therapies

Antiviral therapies encompass pharmaceutical agents designed to inhibit viral replication, entry, assembly, or release within host cells, distinguishing them from vaccines or antibiotics by directly targeting virus-specific processes while minimizing disruption to host machinery. These drugs emerged in the late 20th century, with idoxuridine approved in 1962 for herpes keratitis and acyclovir in 1982 for herpes simplex virus infections, marking the first effective nucleoside analog. Efficacy depends on timely administration, often within 48 hours of symptom onset for acute infections like influenza, and combination regimens for chronic ones like HIV to suppress viral loads below detection thresholds. Mechanisms of action vary by class: / analogs such as acyclovir mimic to chain-terminate viral in herpesviruses; neuraminidase inhibitors like prevent influenza virion release from host cells; inhibitors such as those in therapy cleave viral polyproteins essential for maturation; and inhibitors like incorporate into viral genomes to halt replication in RNA viruses including SARS-CoV-2. Entry inhibitors block receptor binding or fusion, exemplified by for , while integrase inhibitors prevent proviral DNA integration into host genomes. These targeted approaches exploit viral dependencies but yield narrow-spectrum activity, unlike broad antibiotics, due to viruses' intracellular lifecycle and host cell . For HIV, highly active antiretroviral therapy (HAART) combining reverse transcriptase, protease, and integrase inhibitors has transformed prognosis since 1996, reducing mortality by over 80% in treated populations and enabling viral suppression in 90-95% of adherent patients, though adherence challenges and long-term toxicities persist. Influenza antivirals oseltamivir and zanamivir, FDA-approved in 1999 and 1994 respectively, shorten symptom duration by 1-2 days and reduce complications when initiated early, but adamantane resistance reached near 100% by 2009, limiting their use. Herpes treatments with acyclovir or valacyclovir suppress outbreaks in 70-80% of cases but face resistance rates of 5-10% in immunocompromised hosts due to thymidine kinase mutations. For COVID-19, remdesivir, authorized in 2020, cuts hospitalization risk by 87% in high-risk outpatients, while nirmatrelvir-ritonavir (Paxlovid), approved December 2021, lowers mortality and ICU admission in hospitalized patients compared to remdesivir alone. Resistance arises from mutational escape, accelerated by suboptimal dosing or monotherapy, as seen in where transmitted drug resistance affects 10-15% of new infections and in where resistance clusters emerge sporadically at 1-2% prevalence. resistance involves or alterations, complicating therapy in transplant recipients where alternatives like foscarnet carry risks. Broader challenges include from host off-targeting, poor oral for some agents, and the absence of pan-viral drugs, prompting research into host-targeted therapies like interferons, though these amplify side effects. As of 2025, pipeline advances include long-acting injectables like for , approved June 2025 for twice-yearly prevention with near-complete efficacy in trials, signaling shifts toward sustained-release formulations to combat adherence barriers.

Non-Pharmaceutical Interventions

Non-pharmaceutical interventions (NPIs) refer to measures aimed at reducing viral transmission through behavioral, environmental, or policy changes, such as , , masking, and enhanced , without relying on or drugs. These strategies target the interruption of chains of by limiting close contacts, particularly for respiratory viruses with droplet or spread, and have been employed since ancient times, evolving into formalized practices during outbreaks like the 1918 pandemic where city-wide closures and distancing delayed peaks in some U.S. locations. Empirical evidence indicates NPIs can modestly reduce incidence and reproduction numbers (R_t) for viruses like and , but efficacy depends on compliance, virus transmissibility, and implementation timing, with randomized controlled trials (RCTs) often limited and observational data subject to confounders like voluntary behavior changes. Quarantine and isolation, which separate exposed or infected individuals, have historical precedents dating to the for plague but adapted for viruses, such as the successful of in 2003 through and home of over 1,500 cases in , averting wider spread. For , targeted of traced contacts reduced household secondary attack rates by 50-80% in modeling studies, though broad societal showed variable impacts; a 2024 of 24 studies estimated spring 2020 reduced mortality by only 0.2% on average, with no clear cross-country between stringency and deaths . Critics note that benefits are often overstated in literature due to failure to account for pre-existing trends or substitution effects, such as reduced non-COVID healthcare access leading to excess deaths from other causes. Social distancing measures, including stay-at-home orders and capacity limits, aim to decrease contact rates below the viral R_0 threshold; for , workplace distancing in simulations reduced cases by up to 30% by flattening curves and delaying peaks. During , combinations of distancing and closures lowered R_t by 20-50% in early waves per synthetic control analyses, though a cross-state U.S. study found no significant drop post-shelter-in-place orders after adjusting for baseline trends. Effectiveness wanes with fatigue and evasion, as seen in prolonged implementations correlating with minimal additional mortality reductions beyond initial phases, alongside documented rises in issues and economic disruption. Masking protocols, promoted to block respiratory droplets, yielded inconsistent RCT evidence for influenza-like illnesses; a 2008 cluster RCT in households found no significant reduction in secondary from surgical masks versus controls ( 1.0). For , community masking showed low-to-moderate certainty for symptom reduction in systematic reviews, with observational data linking consistent indoor use to 20-80% lower odds of positivity in some cohorts, but pragmatic trials like DANMASK-19 reported no protection against . efficiency varies by mask type—N95s outperform cloth—but real-world adherence and improper use diminish benefits, and source control effects remain debated amid biases in pro-mask studies from institutions favoring interventionist policies. Hygiene practices, such as handwashing and surface disinfection, provide modest ancillary support; meta-analyses of six RCTs for confirmed hand hygiene alone lowered laboratory-confirmed transmission by 16-21%, with greater effects when combined with respiratory etiquette. Ventilation improvements, an environmental NPI, reduced indoor transmission risks by diluting viral loads, as evidenced by lower attack rates in well-ventilated settings during outbreaks. Overall, while NPIs collectively delayed outbreaks and mitigated overload in high-R_0 scenarios like pandemics, their net utility involves trade-offs, with first-principles assessment revealing that voluntary measures often outperform mandates in sustaining compliance without the collateral harms of .

Applications and Technologies

Therapeutic Applications

Viruses have been engineered as therapeutic agents primarily through three modalities: viral vectors for , oncolytic viruses for selective tumor cell lysis, and bacteriophages for targeted bacterial eradication. These approaches leverage viruses' natural ability to infect host cells and replicate genetic material, but clinical translation has been constrained by , off-target effects, and variable efficacy in human trials. In , modified viruses serve as vectors to insert functional genes into patient cells, addressing genetic deficiencies. (AAV) vectors have achieved regulatory approvals, such as Luxturna () for inherited retinal dystrophy, approved by the FDA in 2017 after demonstrating improved in phase 3 trials. Lentiviral vectors enabled successes in therapies for beta-thalassemia and , with Zynteglo and Casgevy receiving approvals in 2019 and 2023, respectively, based on trials showing transfusion independence in over 80% of patients. However, early failures highlighted risks: a 1999 adenovirus-mediated trial for ornithine transcarbamylase deficiency caused the death of patient due to inflammatory cytokine storm, leading to temporary halts in the field. Similarly, retroviral vectors in (SCID) trials from 2002-2004 induced leukemia in five of 20 children via near oncogenes, underscoring the need for safer integration profiles. Despite these setbacks, over 23 products were approved globally by 2025, primarily using AAV and lentiviruses, though long-term durability remains uncertain in non-integrating systems. Oncolytic virotherapy employs viruses genetically altered to replicate preferentially in and lyse cancer cells, often inducing antitumor immunity. (T-VEC), a modified type 1, was FDA-approved in 2015 for advanced after phase 3 trials showed a 16% durable response rate versus 2% for controls, with median overall survival of 23 months. Adenovirus-based agents like ONCOS-102 have demonstrated safety and partial responses in combination with checkpoint inhibitors for refractory solid tumors in phase 1/2 trials. Recent meta-analyses of trials for intermediate-to-advanced cancers report objective response rates of 20-30%, with improved survival in and head/neck subsets, though efficacy varies by tumor type and immune status. Limitations include rapid antiviral clearance by host immunity, restricting systemic use, and heterogeneous trial outcomes, with no universal survival benefit across all cancers tested by 2025. Bacteriophage therapy utilizes viruses that specifically infect and lyse , offering an alternative to antibiotics amid rising . Phages have shown efficacy in preclinical models, reducing bacterial loads and improving survival in animal infections like Pseudomonas aeruginosa pneumonia, with eradication rates up to 100% in some studies. Compassionate-use cases, such as a 2017 treatment resolving a multidrug-resistant in a patient, highlight rapid bacterial clearance within days. However, randomized clinical evidence remains sparse; phase 2 trials for chronic infections report microbiologic resolution in 70-80% of cases, but placebo-controlled data are limited, and phage resistance can emerge without cocktails. Regulatory hurdles persist, with no widespread approvals by 2025, though phage-antibiotic synergies enhance outcomes and .

Research and Synthetic Viruses

Virological research utilizes diverse techniques to investigate viral biology, including isolation and propagation in susceptible cell lines or embryonated eggs, electron microscopy for structural visualization, and serological assays to detect host immune responses. Molecular approaches such as (PCR), quantitative reverse transcription PCR (qRT-PCR), and next-generation sequencing enable amplification, quantification, and full characterization of viral nucleic acids. These methods facilitate studies on replication cycles, host-virus interactions, and in model organisms like mice or ferrets. Advances in have transformed by permitting the de novo assembly of viral genomes from chemically synthesized nucleic acids, bypassing natural templates. This capability supports systems, where targeted mutations reveal functional elements, and enables reconstruction of extinct or unculturable viruses for development. A achievement occurred in 2002 when Eckard Wimmer's team at synthesized the 7.5 kilobase genome by ligating overlapping into full-length cDNA, which was transcribed and transfected into cells to yield infectious virions. These synthetic viruses replicated in culture and induced in transgenic mice expressing human poliovirus receptor, confirming fidelity to wild-type behavior. In 2017, David Evans and colleagues at the University of Alberta reconstructed horsepox virus, an orthopoxvirus ortholog to extinct smallpox, from ten synthetic DNA fragments totaling approximately 212 kilobases ordered from commercial providers. Assembly via recombination in yeast and Shope fibroma virus, followed by serial passage, produced viable virus at a cost of about $100,000, demonstrating scalability for orthopoxvirus vaccine engineering. Synthetic virology has since expanded to RNA viruses like influenza and coronaviruses, aiding gain-of-function experiments and minimal elucidation, though such work underscores the accessibility of recreation via routine molecular tools.

Biotechnological Uses

Viruses serve as versatile tools in , particularly through engineered viral vectors that facilitate targeted into host cells. These vectors exploit the natural of viruses, such as adeno-associated viruses (AAV), lentiviruses, and adenoviruses, to transport therapeutic genetic material while minimizing pathogenicity by removing replication genes. AAV vectors, for instance, achieve long-term in non-dividing cells due to their episomal persistence, making them suitable for treating genetic disorders. Lentiviral vectors integrate transgenes into the host , enabling stable expression in dividing cells, as demonstrated in applications for therapies. Bacteriophages, viruses specific to bacteria, underpin phage therapy as a biotechnological alternative to antibiotics, selectively lysing target pathogens without disrupting beneficial microbiota. This approach targets multidrug-resistant bacteria, with phages engineered for enhanced specificity and efficacy in treating infections like those caused by Pseudomonas aeruginosa or Staphylococcus aureus. Phage display technology further extends applications, allowing the screening of peptide libraries for binding affinities in drug discovery and diagnostics. In and , viruses function as self-assembling scaffolds for nanomaterial fabrication. Plant viruses, such as (TMV), provide symmetrical protein capsids that can be chemically modified to template metal nanowires or encapsulate imaging agents. These viral nanoparticles enable precise and biosensors, leveraging the virus's monodisperse size (typically 10-300 nm) for biocompatibility and multifunctionality. Bacterial viruses like M13 phages are similarly used to create conductive nanowires by aligning under electric fields, advancing applications in and environmental sensing.

Weaponization Risks

The weaponization of viruses involves or deploying them as biological agents to cause mass casualties, disrupt societies, or achieve strategic objectives, exploiting their transmissibility, stability in aerosols, and potential for genetic modification. Respiratory viruses like and filoviruses such as are particularly suited due to high fatality rates and person-to-person spread, though technical challenges include maintaining viability during dissemination and countering immune responses. During the , the Soviet Union's program developed offensive viral weapons, including weaponized virus stored in tons for ICBM delivery and adapted for deployment, violating the 1972 (BWC) which prohibits development, production, and stockpiling of microbial agents for hostile purposes. A 1971 field test near the released , infecting lab workers and civilians, resulting in 10 deaths and requiring emergency to contain the outbreak. The program, spanning over 50 facilities and 50,000 personnel, also explored as an incapacitant. In contrast, the terminated its biological weapons efforts in 1969, destroying stocks and ratifying the BWC in 1975, though earlier research examined viral agents like and . No confirmed wartime use of viral bioweapons has occurred, but post-BWC violations highlight enforcement gaps, as the lacks robust verification mechanisms, relying on voluntary . attempts with viruses remain rare and unsuccessful; groups like focused on , while hypothetical threats include non-state actors acquiring eradicated viruses from labs or synthesizing them via , as demonstrated by the 2018 recreation of horsepox—a relative—for under $100,000. Advances in amplify risks by enabling de novo virus assembly, enhancement, or immune evasion, potentially allowing "stealth" indistinguishable from natural outbreaks. Dual-use research, such as gain-of-function experiments increasing transmissibility in H5N1 , blurs defensive and offensive lines, with concerns over lab in under-resourced facilities. Non-proliferation efforts include export controls on dual-use equipment and the Australia Group's lists, but proliferation to rogue states or terrorists persists as a low-probability, high-impact , underscored by unsecured Soviet-era post-1991 dissolution.

Controversies and Critical Perspectives

Gain-of-Function Research

Gain-of-function (GOF) research entails laboratory manipulations of pathogens, such as viruses, to confer new or enhanced biological properties, including increased transmissibility, virulence, host range, or evasion of immunity. These modifications often involve genetic engineering, serial passaging in cell cultures or animal models, or chimeric virus construction to study potential evolutionary pathways or develop medical countermeasures. Proponents argue it aids in anticipating pandemic threats and informing vaccine design, though empirical evidence for these benefits remains contested, with critics noting that observational surveillance and computational modeling can achieve similar insights without the hazards of creating more dangerous agents. A pivotal episode occurred in 2011 when researchers Ron Fouchier at Erasmus Medical Center and Yoshihiro Kawaoka at the of Wisconsin-Madison independently engineered highly pathogenic A(H5N1) viruses to become airborne-transmissible among ferrets, mammalian models for human influenza spread. Fouchier's team achieved this through 10 serial passages in ferrets after introducing five mutations, enabling mammal-to-mammal transmission without prior adaptation to humans, while Kawaoka created a hybrid with 2009 H1N1 components that similarly spread via respiratory droplets. These experiments, funded by the U.S. (NIH) and others, sparked global alarm over risks and dual-use potential, prompting the U.S. National Science Advisory Board for Biosecurity (NSABB) to initially recommend withholding publication details, though full papers appeared in 2012 after debate. The work demonstrated that H5N1 required only limited mutations for enhanced transmissibility, heightening concerns about natural or lab-induced pandemics. In response, the Obama administration imposed a federal funding pause on October 17, 2014, for GOF studies reasonably anticipated to enhance the transmissibility or virulence of , , or in mammals, citing inadequate risk-benefit assessments and recent lab incidents like the 2014 CDC exposure and H5N1 mishandling. The moratorium halted new and ongoing projects pending a deliberative process involving risk assessments, though it excluded development or basic not aimed at enhancement. This pause lasted until December 19, 2017, when the U.S. Department of Health and Human Services (HHS) lifted it under the Potential Pathogen Care and Oversight (P3CO) Framework, establishing multidisciplinary pre-funding reviews for proposed research on enhanced potential pathogens (ePPPs), weighing scientific merit against risks and requiring stringent protocols. GOF applications extended to coronaviruses, exemplified by NIH grants to from 2014 to 2019 totaling over $3.7 million, of which approximately $600,000 subawarded to the (WIV) for studying bat SARS-like coronaviruses. Experiments involved inserting cleavage sites into spike proteins and serial passaging chimeric viruses in humanized mice and bat cells, resulting in viruses more infectious than parental strains, as reported in a 2015 paper co-authored by WIV's . In 2021, NIH acknowledged that EcoHealth violated grant terms by failing to promptly report enhanced viral growth in mice—up to 10,000 times over baseline—but classified it outside strict P3CO GOF definitions, a determination disputed by critics who argue the functional enhancements met enhancement criteria under broader virological understandings. Risks of GOF include accidental release through lab leaks—precedents include three escapes from Asian labs in 2003-2004 and the 1977 H1N1 re-emergence linked to a Soviet trial mishap—potentially sparking uncontrolled outbreaks, especially with ePPPs requiring BSL-3 or BSL-4 where human errors persist despite protocols. Benefits, such as elucidating pathways for or accelerating strains, are touted by researchers but empirically unproven to outweigh dangers, as alternative methods like or epidemiological modeling suffice for prediction without creating live threats, and historical GOF contributions to remain anecdotal amid institutional incentives favoring funded high-risk work. Oversight challenges persist, with a 2023 GAO report noting HHS's inconsistent ePPP identification and monitoring, underscoring systemic gaps in enforcing frameworks amid academic pressures to minimize risks for continued . Sources defending GOF, often from funded virologists, exhibit potential conflicts, while risk assessments draw from documented failures rather than optimistic projections.

Laboratory Origin Hypotheses

The laboratory origin hypothesis posits that , the virus causing , emerged from research activities at the (WIV), potentially through an accidental leak during gain-of-function experiments on bat coronaviruses. This theory gained traction due to the WIV's documented work on enhancing the transmissibility of sarbecoviruses, funded in part by U.S. grants via , which supported serial passaging of viruses in humanized models to increase pathogenicity. Proponents argue that the absence of a verified intermediate host after extensive searches, combined with the virus's first detection in —home to the world's foremost bat coronavirus research facility—renders a lab-related incident more parsimonious than a natural spillover requiring undetected wildlife trade chains. A key feature cited in support is the cleavage site (FCS) in SARS-CoV-2's , a polybasic insertion (PRRA) absent in closely related sarbecoviruses like , which shares 96.2% genomic identity but lacks this motif enhancing human cell entry. While FCS motifs occur in distant coronaviruses, their rarity in SARS-like viruses and the precise codon usage (avoiding optimal CGG codons often used in lab constructs) have been interpreted by some as signatures of or under lab conditions rather than natural . Experiments at WIV, including those creating chimeric viruses with enhanced lethality, align with such capabilities, though direct precursors remain undisclosed. Circumstantial evidence includes reports of WIV researchers falling ill with COVID-like symptoms in November 2019, predating the officially recognized outbreak, and lapses at the institute, such as inadequate training for BSL-4 protocols. U.S. assessments vary, with the Department of and FBI concluding a lab origin with moderate to low confidence, citing undisclosed WIV illnesses and research on viruses matching SARS-CoV-2's backbone. Critiques of natural origin proponents highlight early private communications among authors of the "Proximal Origin" , who initially deemed a lab escape plausible before publicly favoring , amid pressures from NIH officials like to counter the hypothesis—suggesting institutional incentives to downplay lab risks given funding ties. Sources dismissing the lab hypothesis, often from academia or WHO panels, frequently exhibit systemic biases, including reliance on Chinese data access limited by Beijing's opacity and collaborations with WIV affiliates, which may prioritize geopolitical narratives over empirical scrutiny. No smoking-gun evidence exists for either origin, but the lab theory's viability persists due to historical precedents of lab leaks (e.g., 1977 H1N1 influenza re-emergence) and the failure to identify zoonotic progenitors despite genomic surveillance efforts. Ongoing calls for transparency, including WIV database restorations and raw early case sequences, underscore unresolved causal uncertainties.

Debates on Viral Etiology

Critics of viral argue that viruses have not been rigorously demonstrated to cause , pointing to shortcomings in isolation and fulfillment of causation criteria originally developed for . Koch's 1884 postulates required isolation in pure , reproduction of upon into healthy hosts, and re-isolation of the identical agent, but these cannot be applied to viruses, which are obligate intracellular parasites incapable of independent replication. In 1937, virologist Thomas Rivers proposed adapted criteria emphasizing association with , propagation in , induction of comparable in hosts, immunological specificity, and re-isolation, yet detractors contend even these are compromised by reliance on cell cultures supplemented with and antibiotics, where observed cytopathic effects (CPE) may result from nutritional deprivation or toxicity rather than viral activity. Experiments by Stefan Lanka demonstrated CPE in uninoculated controls under similar conditions, suggesting methodological artifacts underpin claims of viral isolation. A prominent example is Lanka's 2011 challenge offering €100,000 for proof of the measles virus's existence via a single publication meeting six specified criteria, including direct causation . After Bardens submitted , a 2015 district court initially ordered payment, but the 2016 Federal Court of Justice overturned it, ruling the papers failed Lanka's exact terms by spanning multiple studies rather than one comprehensive source. Virus skeptics interpret this as validation of unproven , arguing no satisfies strict isolation without host-derived contaminants or fulfills transmission in healthy, non-stressed subjects. Proponents of terrain theory extend this critique, positing that so-called viral particles are endogenous exosomes or cellular debris arising from metabolic toxicity and internal disequilibrium, not exogenous pathogens invading a healthy , as evidenced by variable outcomes among similarly exposed individuals. Mainstream virology maintains that Rivers' criteria and subsequent molecular adaptations, such as Fredricks and Relman's sequence-based postulates, are satisfied for many viruses through consistent genomic detection in diseased tissues, specific responses, and experimental fulfillment in animal models or limited human challenges. For instance, met Rivers' requirements via isolation from patients, serial propagation, and disease induction in ferrets and hamsters with re-isolation of matching strains. Epidemiological patterns, including outbreak cessation post-vaccination correlating with titers against viral antigens, further support , though ethical constraints limit direct human transmission proofs. These debates persist amid institutional tendencies to marginalize dissent as , potentially sidelining scrutiny of virological assumptions entrenched since .

Critiques of Public Health Narratives

Critiques of narratives surrounding viral outbreaks, particularly the , have centered on the empirical effectiveness of interventions like lockdowns and mask mandates, as well as the suppression of dissenting scientific viewpoints. A of early 2020 lockdowns across and the estimated they reduced mortality by only 0.2% on average, suggesting limited direct impact relative to the socioeconomic disruptions caused. Similarly, another found that spring 2020 lockdowns had a relatively small effect on mortality, with benefits often overstated in initial messaging that emphasized "" to prevent healthcare collapse without quantifying downstream harms such as delayed treatments for non-COVID conditions. data from 2020-2023 revealed discrepancies, with U.S. excess deaths totaling over 1 million in 2020-2021 alone—exceeding reported COVID-attributed deaths—attributable in part to indirect effects like disrupted medical care, challenging narratives that attributed nearly all excess deaths solely to the virus. Mask mandates faced scrutiny for relying on observational data rather than robust randomized controlled trials (RCTs), with meta-analyses noting that while some evidence suggested modest reductions in transmission, high-quality RCTs were scarce and showed inconsistent results, such as an 18% reduction for wearers in one trial but no clear community-level efficacy in others. Early guidance from figures like on February 5, 2020, stated masks were unnecessary for the general public to conserve supplies for healthcare workers, contradicting later mandates that portrayed masks as essential despite evolving evidence and without addressing potential physiological burdens like increased respiratory effort. Public health campaigns often presented these measures as unequivocally life-saving, yet systematic reviews highlighted that benefits were context-dependent and frequently outweighed by compliance challenges and opportunity costs, including declines and economic fallout not adequately weighed in formulations. A recurring critique involves the institutional suppression of alternative perspectives, reflecting potential biases in agencies like the NIH and platforms influenced by government pressure. The , authored by epidemiologists , , and in October 2020, advocated focused protection for vulnerable groups over blanket lockdowns to minimize broader harms; it garnered over 15,000 signatures from scientists and medical professionals but faced immediate , including downranking its website and social media of signatories. U.S. government communications with tech firms led to indirect of such views, as ruled in federal court, eroding public trust in narratives that dismissed heterodox approaches without engaging their evidence-based arguments on age-stratified risks. Similarly, early dismissal of the lab-leak hypothesis as a "conspiracy theory" by NIH leaders, including Fauci, involved coordinated efforts to influence publications like "Proximal Origin," despite private acknowledgments of its plausibility, prioritizing institutional narratives over open inquiry. These actions, documented in congressional investigations, underscore how systemic alignments in institutions—often critiqued for left-leaning biases—stifled debate, as evidenced by Fauci's later testimony admitting an "open mind" on origins after initial public rejections. Mandatory vaccination policies, framed as critical for , have been faulted for underestimating waning efficacy and overemphasizing absolute risk reduction, leading to eroded vaccine confidence and compliance with future measures. Fauci's shifting stance on —denying U.S. funding of such work at the despite of NIH grants to for related bat coronavirus experiments—further fueled perceptions of narrative inconsistencies, as emails revealed private concerns about lab safety risks not conveyed publicly. Overall, these critiques argue that narratives prioritized consensus over causal from first-principles analysis of transmission dynamics and intervention trade-offs, with lasting impacts on institutional credibility amid documented overreach.

References

Add your contribution
Related Hubs
Contribute something
User Avatar
No comments yet.